Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis

Edward Burn^{1,2*}, Xintong Li^{2*}, Antonella Delmestri², Nathan Jones², Talita Duarte-Salles¹, Carlen Reyes¹, Eugenia Martinez-Hernandez³, Edelmira Marti⁴, Katia MC Verhamme⁵, Peter R Rijnbeek⁵, Victoria Y Strauss^{2†}, Daniel Prieto-Alhambra^{2,5†}

¹Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain, ²Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, UK, ³Department of Neurology, Hospital Clinic and University of Barcelona, Barcelona, Spain, ⁴Hemostasis and Thrombosis Unit, Hematology Department, Hospital Clínico Universitario de Valencia, Spain, ⁵Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands

*Joint first authors, [†]Joint senior authors

Corresponding author: Prof Daniel Prieto-Alhambra, Botnar Research Centre, Windmill Road, OX37LD, Oxford, UK, daniel.prietoalhambra@ndorms.ox.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Objectives

To calculate the observed rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2, infection with SARS-CoV-2, and to compare them to background (expected) rates in the general population.

Design

Cohort study using routinely collected primary care records.

Setting

Routine practice in the United Kingdom.

Participants

Two mutually exclusive vaccinated cohorts included people vaccinated with either ChAdOx1 or BNT162b2 between 8 December 2020 and 6 March 2021. A third cohort consisted of people newly infected with SARS-Cov-2 identified by a first positive RT-PCR test between 1 September 2020 and 28 February 2021. The fourth general population cohort for background rates included those people with a visit between 1 January 2017 and 31 December 2019. In total, we included 1,868,767 ChAdOx1 and 1,661,139 BNT162b2 vaccinees, 299,311 people infected with SARS-CoV-2, and 2,290,537 people from the general population.

Interventions

First-dose of either ChAdOx1 or BNT162b2

Main outcome measures

Outcomes included venous thrombosis, arterial thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia. Outcome rates were estimated for recipients of the ChAdOx1 or BNT162b2 vaccines, for people infected with SARS-CoV-2, and background rates in the general population. Indirectly standardized incidence ratios (SIR) were estimated.

Results

We included 1,868,767 ChAdOx1 and 1,661,139 BNT162b2 vaccinees, 299,311 people infected with SARS-CoV-2, and 2,290,537 people from the general population for background rates. The SIRs for pulmonary embolism were 1.23 [95% Cl, 1.09-1.39] after vaccination with ChAdOx1, 1.21 [1.07-1.36] after vaccination with BNT162b2, and 15.31 [14.08 to 16.65] for infection with SARS-CoV-2. The SIRs for thrombocytopenia after vaccination were 1.25 [1.19 to 1.31] for ChAdOx1 and 0.99 (0.94 to 1.04) for BNT162b2. Rates of deep vein thrombosis and arterial thrombosis were similar among those vaccinated and the general population.

Conclusions

ChAdOx1 and BNT162b2 had broadly similar safety profiles. Thrombosis rates after either vaccine were mostly similar to those of the general population. Rates of pulmonary embolism increased 1.2-fold after either vaccine and 15-fold with SARS-CoV-2 infection. Thrombocytopenia was more common among recipients of ChAdOx1 but not of BNT162b2.

Summary box

What is already known on this topic

- Spontaneous reports of unusual and severe thrombosis with thrombocytopenia syndrome (TTS) raised concerns regarding the safety of adenovirus-based vaccines against SARS-CoV-2
- In a cohort study including over 280,000 people aged 18-65 years vaccinated with ChAdOx1 in Denmark and Norway, Pottegård et al reported increased rates of venous thromboembolic events as well as thrombocytopenia among vaccine recipients.

What this study adds

- In this cohort study, ChAdOx1 and BNT162b2 were seen to have broadly similar safety profiles.
- Rates of thrombosis after either vaccine were generally similar to those of the general population. Rates of pulmonary embolism were though 1.2-fold higher than background rates after either vaccine, which compared to 15-fold higher after SARS-CoV-2 infection.
- Thrombocytopenia was more common among recipients of ChAdOx1 but not of BNT162b2.

Introduction

Vaccines against SARS-CoV-2 have been developed rapidly using a number of platforms. The ChAdOx1 nCoV-19 (Oxford–AstraZeneca; ChAdOx1) and BNT162b2 mRNA (Pfizer– BioNTech; BNT162b2) vaccines received approval for use in the United Kingdom on 8 and 31 December 2020, respectively. Evidence from clinical trials and real-world data has shown these vaccines to be highly effective in preventing symptomatic COVID-19, severe disease, and hospitalization.^{1–7}

As COVID-19 vaccines have been approved under emergency authorization, they must continue to be monitored to assess their safety. Instances of rare adverse events have been identified alongside the ongoing nationwide immunization programs.^{8–10} A particular concern has arisen regarding thrombotic events, with concurrent thrombocytopenia reported among individuals vaccinated with adenovirus-based vaccines against SARS-CoV-2. As of 26 May 2021, 348 spontaneous reports of major thromboembolic events with thrombocytopenia had been documented following 24 million first doses and 13 million second doses of the ChAdOx1 vaccine in the UK.¹¹ Although fewer concerns have been raised about safety signals for BNT162b2, instances of immune thrombocytopenia have also been observed among recipients of this vaccine.¹²

In this study, we estimated the incidence of thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia over the 28 days following a first dose of the ChAdOx1 and BNT162b2 vaccines and compared these rates with historical, pre-pandemic rates in the general population. To provide additional context, we also studied the rates of these events after a positive RT-PCR test for SARS-CoV-2.

Methods

Study design, setting, and data sources

People vaccinated against SARS-CoV-2 and people infected with SARS-CoV-2 were identified from Clinical Practice Research Datalink (CPRD) AURUM. A background cohort was obtained from CPRD GOLD to estimate pre-pandemic background rates. AURUM and GOLD are established primary care databases broadly representative of the UK population,^{13,14} and previous research has demonstrated their validity for vaccine safety surveillance.^{15,16} Both databases were mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) for analysis.¹⁷

Study participants and follow-up

Four cohorts were studied. Two mutually exclusive vaccinated cohorts included people vaccinated with either ChAdOx1 or BNT162b2 between 8 December 2020 and 6 March 2021. They were followed for up to 28 days from their first vaccination (index date). A third cohort consisted of people newly infected with SARS-Cov-2 identified by a first positive RT-PCR test between 1 September 2020 and 28 February 2021. The test date was used as the index date. They were followed for up to 90 days. The fourth cohort, a general population background cohort, included people who had a primary care visit or contact recorded between 1 January 2017 and 31 December 2019. That first visit or contact was used as the index date and follow-up ran up to 31 December 2019.

All participants were required to be aged 30 years or older and, for the primary analysis, have at least 1 year of prior history available. Participants did not contribute to an analysis if they had the same event recorded in the year before their index date. Time at risk was censored if an individual had the outcome of interest or exited the database before the end of follow-up.

Sensitivity analyses were conducted removing the requirements of a year of prior history and, for the background population, a primary care visit or contact. For the latter, 1 January 2017 was used as the index date.

Study outcomes

We used diagnostic codes to identify five venous thromboembolic events: cerebral venous sinus thrombosis (CVST), deep vein thrombosis (DVT), pulmonary embolism (PE), splanchnic vein thrombosis (SVT), and the composite event venous thromboembolism (VTE), which encompassed DVT and PE. We identified two arterial thromboembolic events (ATE): myocardial infarction and ischemic stroke. We also used an overall stroke definition that included non-specific, hemorrhagic, and ischemic stroke codes.

Thrombocytopenia was identified using diagnostic codes and laboratory data showing platelets count between 10,000 and 150,000 platelets per microliter, based on the Brighton collaboration definition.¹⁸ Immune thrombocytopenia was identified using diagnostic codes.

Thrombosis with thrombocytopenia syndromes (TTS) was identified where thrombocytopenia was observed within 10 days before or after thrombosis. This time window was broadened in a sensitivity analysis.

Results for additional related outcomes (intestinal infarction, platelet disorder, portal vein thrombosis, and thrombocytopenic purpura) are reported in the Appendix.

Statistical methods

For each cohort and outcome of interest, we describe the cohort's age, sex, comorbidities, and medication use within 6 months before and up to 4 days before the index date. We report the number of events observed and crude incidence rates per 100,000 person-years with 95% confidence intervals (CIs). We used indirect standardization with the background cohort as the standard to estimate the number of events expected for the vaccination and SARS-CoV-2 cohorts if their risk was the same as that of the general population.¹⁹ We estimated standardized incidence ratios (SIRs) and 95% confidence intervals comparing observed and expected rates. We stratified all analyses by 10-year age bands and sex and analyses of those vaccinated by calendar month. We calculated the standardized event difference proportion to provide a measure of absolute risk. To avoid re-identification, we do not report any analysis with under 5 cases.

The study protocol was published in the EU PAS Register (EUPAS40414). The use of CPRD data was approved by the Independent Scientific Advisory Committee (21_000391 and 20_000211). All analytical code is available at: <u>https://github.com/oxford-pharmacoepi/CovidVaccinationSafetyStudy</u>.

Patient and public involvement

No patients or members of the public were directly involved in the study design or its execution.

Results

We included 1,868,767 people vaccinated with ChAdOx1, 1,661,139 people vaccinated with BNT162b2, 299,311 people infected with SARS-CoV-2, and 2,290,537 people from the general population. The two vaccinated populations were similar in terms of age, sex, and clinical characteristics The vaccinated populations were older, more often female, and had a higher prevalence of all studied comorbidities than the general population. Differences in the prevalence of comorbidities was more pronounced for younger age groups. Those infected with SARS-CoV-2 were younger than the general population. Detailed characteristics for all four cohorts are given in Table 1, and stratified by age in the Appendix. BNT162b2 vaccination started earlier than ChAdOx1 vaccination. The numbers vaccinated with the two vaccines became similar in late January 2021, and ChAdOx1 vaccines predominated in February and early March (Figure 1).

Rates of VTE were higher in men aged 50-59 vaccinated with BNT162b2 (367.5/100,000 person-years [95%CI 237.8-542.5]) than the age-sex specific background rate (211.9/100,000 person-years [200.2-224.1]) (Figure 2). Rates of VTE were also higher in women aged \geq 80 vaccinated with ChAdOx1 (878.1/100,000 person-years [685.8-1107.6]) than the equivalent age-sex background (703.0/100,000 person-years [670.1-737.2]). Standardized SIRs for VTE were 1.07 [0.98-1.18] for ChAdOx1, 1.09 [1.00-1.20] for BNT162b2, and 8.08 [7.48-8.72] for SARS-Cov-2 (Table 2, Figure 3).

Although crude rates of DVT post-vaccination were higher than expected in some strata (Figure 2), standardization attenuated this difference, with SIRs of 0.95 [0.83-1.08] for ChadOx1 and 1.01 [0.89-1.14] for BNT162b2 (Figure 3). DVT rates after SARS-Cov-2 infection were more than double the expected rates, with a SIR of 2.56 [2.15-3.05].

Post-vaccination rates of PE were higher than expected in some strata, such as women and men aged 50-59, women aged >=80 vaccinated with ChAdOx1, and men aged 60-69 vaccinated with BNT162b2 (Figure 2). After standardization, excess PE events remained for ChAdOx1 and Bnt162n2, with SIRs of 1.23 [1.09-1.39] and 1.21 [1.07-1.36], respectively. In comparison, SARS-Cov-2 infection had a SIR of 15.31 [14.08-16.65]. Incidence rate ratios by age and sex for PE and the profiles of those with an event are summarized in the Appendix.

Few occurrences of SVT were seen, with a SIR of 1.38 [0.72-2.66] for ChAdOx1 and under 5 cases following BNT162b2 vaccination or SARS-Cov-2 infection. CVST was too rare (n<5) in all three cohorts to conduct the primary analyses (see Figure 3 and below for results from sensitivity analyses).

Observed post-vaccination ATE rates were similar to expected rates (Figure 2). There were fewer ATE than expected for both vaccinated cohorts after standardization (Table 2, Figure 3). Little differences was seen between observed and expected ATE in people infected with SARS-Cov-2 (Figure 3). When analyzed separately, observed rates of myocardial infarction and ischemic stroke were also similar to expected rates following both vaccination and infection with SARS-Cov-2 (Figure 2, Figure 3).

Thrombocytopenia was more common than expected after vaccination with ChAdOx1 (SIR 1.25 [1.19-1.31]), but not after vaccination with BNT162b2 (SIR 0.99 [0.94-1.04]). Immune thrombocytopenia was more common than expected from the background population after vaccination with ChAdOx1 (SIR 2.01 [1.27-3.19]), BNT162b2 (SIR 1.74 [1.05-2.89]), and SARS-Cov-2 infection (SIR 2.83 [1.18-6.80]). Incidence rate ratios by age and sex for

thrombocytopenia are summarized in the Appendix, along with the profiles of those affected.

VTE with concurrent thrombocytopenia was very rare and had similar crude rates in the background population (3.5/100,000 person-years [3.1-4.1]), after ChAdOx1 vaccination (5.9 [2.4-12.1]), and after BNT162b2 vaccination (5.1 [1.9-11.0]). There were fewer than 5 cases in the SARS-Cov-2 cohort. Standardization confirmed this finding, with SIRs of 1.09 [0.52-2.29] for ChAdOx1 and 0.86 [0.39-1.92] for BNT162b2.

ATE with thrombocytopenia was also very rare, with a rate after ChAdOx1 vaccination of 4.2/100,000 person-years [1.4-9.8] and an overall crude background rate of 1.7/100,000 person-years [1.4-2.1], equivalent to a SIR of 1.57 [0.65-3.78]. Fewer than 5 cases were identified after BNT162b2 vaccination and SARS-Cov-2 infection.

Overall crude rates of stroke with thrombocytopenia were 1.4/100,000 person-years [1.1-1.8] in the background population and 5.0 [1.8-11.0] after vaccination with ChAdOx1, equivalent to a SIR of 2.21 [0.99 to 4.91]. Again, under 5 cases were seen after BNT162b2 vaccination and SARS-Cov-2 infection, so SIR rates were not estimated. Myocardial infarction with thrombocytopenia was too rare (n<5) in the vaccination and infection cohorts for analysis.

Sensitivity analyses

Results from sensitivity analyses were generally consistent with the results from the primary analyses (see Appendix). One key addition was the analysis of CVST, which was too rare for estimation in the primary analyses but could be analyzed when the requirement of a year of prior history was removed. The observed number of CVST events (n=5) was then higher than expected (2.2) in the ChAdOx1 cohort, resulting in a SIR of 2.32 [0.97-5.58] (Table 2, Figure 3).

All primary and sensitivity analysis results are available in an interactive web application: <u>https://livedataoxford.shinyapps.io/CovidVaccinationSafetyStudy/</u>

Discussion

Summary of results

In a cohort of 3.5 million people vaccinated against SARS-CoV-2, 74 (0.002%) more than expected suffered a VTE in the 28 days following vaccination. This higher rate was driven by more PE events after both ChAdOx1 and BNT162b2 than expected, with a 20% increase in rates of events and 93 (0.003%) excess PEs observed. The rate of PE was much larger in people infected with SARS-Cov-2, with a 15-fold relative increase and 511 (0.17%) excess PE events observed in 300,000 people.

Although observed rates of thrombocytopenia were similar to expected for people vaccinated with BNT162b2, a 25% relative increase in the rate of thrombocytopenia was seen among those vaccinated with ChAdOx1. This increase was most pronounced for younger age groups. No signal was seen for either vaccine for ATE. Finally, 3 (0.0001%) more cases than expected were seen of CVST and 3 (0.0002%) of stroke with thrombocytopenia in 1.8 million people vaccinated with ChAdOx1 in a secondary analysis.

Noticeable differences in comorbidities between the vaccinated and background cohorts suggest the potential for residual confounding, unaccounted for in our analyses.

Findings in context

Concerns over thrombosis – alone and with thrombocytopenia – have been raised from spontaneous reports data since March.^{8,9,20} Case series have been published, suggesting a new clinical entity known as vaccine-induced immune thrombotic thrombocytopenia (VITT), presenting as unusual thrombosis with raised antibodies against platelet factor 4. Only a few small studies have been conducted on this topic. A study of 280,000 vaccinees aged between 18 and 65 in Denmark and Norway assessed the 28-day incidence rates of thromboembolic events and coagulation disorders following ChAdOx1.²¹ Similar to our analyses, Pottegård et al applied a historical comparator design with indirect standardization. They found a 2-fold increased rate of VTE, an 80% increase in rates of PE, and a 20-fold increased rate of CVST. The authors also reported a 3-fold higher-than-expected rate of thrombocytopenia and a potential increase. As in our study, they observed similar rates of arterial events among those vaccinated as would be expected given rates in the general population.

More recently, a nested case-control study from Scotland found no increase in risk of VTE with either vaccine.²² The authors also reported potential increased risks of ATE and hemorrhagic events with ChAdOx1, although these were not confirmed in subsequent self-controlled case series analysis. The authors suggested that residual confounding could explain their findings. Case-control analyses based on routine health data have recently been criticized and shown to induce substantial residual bias,²³ which may explain the differences in results from those in our study and that by Pottegård et al.

Study strengths and limitations

Our study has limitations. The time period studied covered the initial phases of vaccination in the UK, when vaccines were prioritized for older, more vulnerable populations and healthcare staff.²⁴ We therefore saw a higher prevalence of conditions such as asthma and diabetes in those vaccinated than in the general population. Although we used indirect

standardization to account for differences in the four cohorts' age distributions, remaining residual confounding could explain some of our findings. Such bias could result in overestimated safety signals due to remaining imbalances in the baseline outcome risk when comparing vaccinated and background populations.

Measurement error is unavoidable in observational studies. However, any errors are likely to have been non-differential across our vaccinated and unvaccinated cohorts and should therefore not have affected our relative rate estimates. As we only used primary care data, we may have underestimated absolute risks due to a lack of hospital linkage. However, previous studies have shown that CPRD captures rare events well, even without linkage to Hospital Episode Statistics.²⁵

Although within-database comparisons are preferred,¹⁶ we had to use two slightly different primary care databases. However, one study found that these databases gave similar results.²⁶ We also used the OMOP common data model to maximize the comparability of the two databases irrespective of differences in their coding systems.

Our study also has strengths. This is the largest cohort study on the safety of COVID-19 vaccines to date. The large sample of 3.5 million vaccinees allowed us to assess very rare events that are generally not observed in clinical trials. We used a well-established source of routinely collected health data previously used for vaccine safety studies.^{27,28} Including cohorts of people infected with SARS-CoV-2 and the general population provided much needed context for interpreting our findings. Our historical comparison method ensured a timely study with high statistical power. Our protocol was pre-specified and agreed in advance with the study funder, the European Medicines Agency. Our analyses were based on data recorded before the detection of thrombosis and thrombocytopenia signals, minimizing surveillance bias.

Conclusions

In a cohort of 3.5 million people vaccinated against SARS-Cov-2, thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia were very rare events. The rates of VTE and ATE were broadly similar after ChAdOx1 and BNT162b2 vaccination, although thrombocytopenia was more common among ChAdOx1 vaccinees, particularly in younger age strata. A potential safety signal for PE for both vaccines was identified. Although the occurrence of PE after vaccination was 1.2-fold above that expected in the general population, its occurrence among those contracting SARS-CoV-2 was more than 15-fold the background (expected) rate. Vaccinated people recorded more comorbidities and medicine use than the background population, suggesting potential for unresolved confounding by indication.

References

- 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.
- 2. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99-111.
- Hall VJ, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). Published online February 22, 2021. doi:10.2139/ssrn.3790399
- 4. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. Published online February 19, 2021. doi:10.2139/ssrn.3789264
- 5. Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat Med*. Published online June 9, 2021:1-9.
- 6. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet*. 2021;397(10285):1646-1657.
- Cabezas C, Coma E, Mora-Fernandez N, et al. Effects of BNT162b2 mRNA vaccination on COVID-19 disease, hospitalisation and mortality in nursing homes and healthcare workers: A prospective cohort study including 28,594 nursing home residents, 26,238 nursing home staff, and 61,951 healthcare workers in Catalonia. SSRN Electron J. Published online April 9, 2021. doi:10.2139/ssrn.3815682
- Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med.* 2021;(NEJMoa2104882). doi:10.1056/NEJMoa2104882
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. *N Engl J Med.* 2021;(NEJMoa2104840). doi:10.1056/NEJMoa2104840
- 10. Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas A-M. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. *J Thromb Haemost*. 2021;(jth.15347). doi:10.1111/jth.15347
- 11. MHRA. Coronavirus vaccine weekly summary of Yellow Card reporting: Updated 6 May 2021. Published May 6, 2021. Accessed May 7, 2021. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adversereactions/coronavirus-vaccine-summary-of-yellow-card-reporting
- 12. Lee E-J, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. *Am J Hematol.* 2021;96(5):534-537.
- 13. Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *Int J Epidemiol*. 2019;48(6):1740-1740g.

- 14. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical practice research datalink (CPRD). *Int J Epidemiol*. 2015;44(3):827-836.
- 15. Leite A, Thomas SL, Andrews NJ. Implementing near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD). *Vaccine*. 2017;35(49 Pt B):6885-6892.
- 16. Li X, Ostropolets A, Makadia R, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. *BMJ*. 2021;373:n1435.
- 17. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. *J Am Med Inform Assoc*. 2012;19(1):54-60.
- Chen MD MA R. Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). Published May 18, 2021. Accessed June 13, 2021. https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-Case-Definition-v10.16.3-May-23-2021.pdf
- 19. Kirkwood BR, Sterne JAC. Essential Medical Statistics. 2nd ed. Wiley-Blackwell; 2010.
- 20. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. *N Engl J Med.* 2021;384(23):2202-2211.
- 21. Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *BMJ*. 2021;373:n1114.
- 22. Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. *Nat Med.* Published online June 9, 2021:1-8.
- 23. Schuemie MJ, Ryan PB, Man KKC, Wong ICK, Suchard MA, Hripcsak G. A plea to stop using the case-control design in retrospective database studies. *Stat Med.* 2019;38(22):4199-4208.
- 24. Joint Committee on Vaccination and Immunisation. Priority groups for coronavirus (COVID-19) vaccination: advice from the JCVI. Published online December 30, 2020. https://www.gov.uk/ government/publications/ priority-groups-for- coronavirus-covid-19-vaccination-advice- from-the-jcvi- 30-december-2020
- Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. *Am J Epidemiol.* 2009;169(3):382-388.
- Gulliford MC, Sun X, Anjuman T, Yelland E, Murray-Thomas T. Comparison of antibiotic prescribing records in two UK primary care electronic health record systems: cohort study using CPRD GOLD and CPRD Aurum databases. *BMJ Open*. 2020;10(6):e038767.
- 27. Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. *Lancet Child Adolesc Health*. 2018;2(6):395-403.

28. Grint DJ, McDonald HI, Walker JL, Amirthalingam G, Andrews N, Thomas S. Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. *BMJ Open.* 2020;10(1):e034886.

Table 1. Characteristics of study participants

Characteristics of the participants in the four study cohorts used for the primary analyses. Participants were aged 30 years or older and had at least one year of prior history before index date in the database. Those in the general population had a primary care visit or contact between 2017 and 2019. People infected with SARS-CoV-2 had a confirmatory positive RT-PCR test. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. [†] Medications of interest: non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system.

	General population	Vaccinated with ChadOx1	Vaccinated with BNT162b2	Infected with SARS-CoV-2
Ν	2,290,537	1,868,767	1,661,139	299,311
Age (median [IQR])	54 [43 to 67]	66 [56 to 73]	67 [54 to 78]	48 [39 to 58]
Age: 30 to 39	431,801 (18.9%)	123,991 (6.6%)	135,101 (8.1%)	82,427 (27.5%)
Age: 40 to 49	459,400 (20.1%)	173,453 (9.3%)	178,503 (10.7%)	77,184 (25.8%)
Age: 50 to 59	506,515 (22.1%)	285,938 (15.3%)	279,223 (16.8%)	75,543 (25.2%)
Age: 60 to 69	403,673 (17.6%)	567,041 (30.3%)	322,252 (19.4%)	38,646 (12.9%)
Age: 70 to 79	301,179 (13.1%)	545,251 (29.2%)	372,426 (22.4%)	14,839 (5.0%)
Age: 80 or older	187,969 (8.2%)	173,093 (9.3%)	373,634 (22.5%)	10,672 (3.6%)
Sex: Male	1,094,911 (47.8%)	845,908 (45.3%)	702,863 (42.3%)	136,301 (45.5%)
Years of prior observation time (median [IQR])	13.5 [8.1 to 16.3]	19.0 [7.7 to 31.1]	19.1 [7.8 to 31.2]	12.4 [5.3 to 23.9]

Autoimmune disease	57,773 (2.5%)	72,119 (3.9%)	64,311 (3.9%)	7,136 (2.4%)
Antiphospholipid syndrome	1,046 (0.0%)	1,535 (0.1%)	1,349 (0.1%)	215 (0.1%)
Thrombophilia	2,582 (0.1%)	3,628 (0.2%)	3,192 (0.2%)	549 (0.2%)
Asthma	301,669 (13.2%)	284,126 (15.2%)	253,177 (15.2%)	45,470 (15.2%)
Atrial fibrillation	72,643 (3.2%)	100,730 (5.4%)	117,398 (7.1%)	5,993 (2.0%)
Malignant neoplastic disease	187,499 (8.2%)	257,449 (13.8%)	268,655 (16.2%)	15,663 (5.2%)
Diabetes mellitus	197,619 (8.6%)	306,944 (16.4%)	276,194 (16.6%)	28,488 (9.5%)
Obesity	94,054 (4.1%)	120,052 (6.4%)	98,900 (6.0%)	16,791 (5.6%)
Heart disease	251,708 (11.0%)	334,469 (17.9%)	349,669 (21.0%)	24,511 (8.2%)
Hypertensive disorder	533,750 (23.3%)	677,743 (36.3%)	643,345 (38.7%)	53,921 (18.0%)
Renal impairment	161,596 (7.1%)	207,751 (11.1%)	234,386 (14.1%)	14,150 (4.7%)
Chronic Obstructive Pulmonary Disease	77,205 (3.4%)	107,636 (5.8%)	95,654 (5.8%)	5,384 (1.8%)
Dementia	29,376 (1.3%)	38,589 (2.1%)	34,829 (2.1%)	4,886 (1.6%)
Medication use (183 days pr	ior to four days prior)		· ·	
Non-steroidal anti- inflammatory drugs	618,552 (27.0%)	264,090 (14.1%)	242,309 (14.6%)	33,299 (11.1%)
Cox2 inhibitors	6,115 (0.3%)	1,931 (0.1%)	1,581 (0.1%)	258 (0.1%)
Systemic corticosteroids	263,488 (11.5%)	119,766 (6.4%)	105,977 (6.4%)	14,168 (4.7%)

Antithrombotic and anticoagulant therapies	102,605 (4.5%)	61,322 (3.3%)	65,237 (3.9%)	3,885 (1.3%)
Lipid modifying agents	130,264 (5.7%)	110,329 (5.9%)	102,835 (6.2%)	8,224 (2.7%)
Antineoplastic and immunomodulating agents	57,403 (2.5%)	20,445 (1.1%)	20,541 (1.2%)	3,822 (1.3%)
Hormonal contraceptives for systemic use	76,796 (3.4%)	18,566 (1.0%)	20,491 (1.2%)	7,205 (2.4%)
Tamoxifen	1,957 (0.1%)	814 (0.0%)	799 (0.0%)	87 (0.0%)
Sex hormones and modulators of the genital system	110,583 (4.8%)	44,612 (2.4%)	44,563 (2.7%)	10,283 (3.4%)
Summary count of condition	ns and medications of int	erest	•	
One or more condition of interest*	579,628 (25.3%)	778,559 (41.7%)	751,224 (45.2%)	68,879 (23.0%)
One or more medication of interest †	758,348 (33.1%)	345,875 (18.5%)	318,704 (19.2%)	47,239 (15.8%)
One or more condition/ medication of interest* [†]	1,058,141 (46.2%)	949,193 (50.8%)	897,757 (54.0%)	99,727 (33.3%)

Table 2. Observed versus expected events among people vaccinated against SARS-CoV-2 or with a positive PCR test for SARS-CoV-2

For each event of interest, the number of people contributing to the analysis from the target population, their person-years contributed, and the number of observed events are given. Expected events are estimated using indirect standardization to the general population. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with fewer than 5 occurrences were omitted for privacy reasons: cerebral venous sinus thrombosis and splanchnic vein thrombosis (BNT162b2 and SARS-CoV-2), venous thromboembolism with thrombocytopenia (SARS-CoV-2), and myocardial infarction or ischemic stroke with thrombocytopenia (BNT162b2 and SARS-CoV-2). *Cerebral venous sinus thrombosis is reported without the requirement for a year of prior history as fewer than 5 events were seen when this restriction was imposed.

	N	Person- years	Observed events	Expected events	Standardised event difference proportion %	SIR (95% CI)
Thrombosis						
Cerebral venous sinus thrombosis (CVST)*						
Vaccinated with ChAdOx1	1,956,1 36	124,569	5	2.2	0.0001%	2.32 (0.97 to 5.58)
Deep vein thrombosis (DVT)						
Vaccinated with ChAdOx1	1,863,6 68	118,809	226	237.9	-0.0006%	0.95 (0.83 to 1.08)
Vaccinated with BNT162b2	1,656,8 75	118,344	254	251.3	0.0002%	1.01 (0.89 to 1.14)


	-				r	
SARS-CoV-2 PCR positive test	298,776	40,528	125	48.8	0.0255%	2.56 (2.15 to 3.05)
Pulmonary embolism (PE)						
Vaccinated with ChAdOx1	1,863,4 03	118,787	259	210.4	0.0026%	1.23 (1.09 to 1.39)
Vaccinated with BNT162b2	1,656,7 55	118,336	261	216.4	0.0027%	1.21 (1.07 to 1.36)
SARS-CoV-2 PCR positive test	298,786	40,491	547	35.7	0.1711%	15.31 (14.08 to 16.65)
Splanchnic Vein Thrombosis (SVT)						
Vaccinated with ChAdOx1	1,868,5 36	119,132	9	6.5	0.0001%	1.38 (0.72 to 2.66)
Venous thromboembolism (VTE)						
Vaccinated with ChAdOx1	1,858,8 37	118,483	461	429.2	0.0017%	1.07 (0.98 to 1.18)
Vaccinated with BNT162b2	1,652,8 92	118,054	491	448.6	0.0026%	1.09 (1.00 to 1.20)
SARS-CoV-2 PCR positive test	298,397	40,429	646	80	0.1897%	8.08 (7.48 to 8.72)
Myocardial infarction						

	1,861,3					
Vaccinated with ChAdOx1	65	118,643	347	411.3	-0.0035%	0.84 (0.76 to 0.94)
Vaccinated with BNT162b2	1,654,0 37	118,145	356	433.4	-0.0047%	0.82 (0.74 to 0.91)
SARS-CoV-2 PCR positive test	298,632	40,509	79	65.7	0.0045%	1.20 (0.96 to 1.50)
Ischemic stroke						
Vaccinated with ChAdOx1	1,867,0 00	119,025	72	95.8	-0.0013%	0.75 (0.60 to 0.95)
Vaccinated with BNT162b2	1,659,6 35	118,542	120	108.5	0.0007%	1.11 (0.92 to 1.32)
SARS-CoV-2 PCR positive test	299,100	40,582	13	12.3	0.0002%	1.05 (0.61 to 1.81)
ATE (Myocardial infarction or ischemic stroke)						
Vaccinated with ChAdOx1	1,858,9 74	118,481	406	503.7	-0.0053%	0.81 (0.73 to 0.89)
Vaccinated with BNT162b2	1,651,9 03	117,990	458	538.3	-0.0049%	0.85 (0.78 to 0.93)
SARS-CoV-2 PCR positive test	298,464	40,485	88	77.6	0.0035%	1.13 (0.92 to 1.40)
Stroke						

Vaccinated with ChAdOx1	1,861,3 58	118,629	413	405	0.0004%	1.02 (0.93 to 1.12)
Vaccinated with BNT162b2	1,654,5 69	118,167	457	454	0.0002%	1.01 (0.92 to 1.10)
SARS-CoV-2 PCR positive test	298,709	40,525	65	54.5	0.0035%	1.19 (0.93 to 1.52)
Thrombocytopenia						
Immune thrombocytopenia						
Vaccinated with ChAdOx1	1,868,3 76	119,120	18	8.9	0.0005%	2.01 (1.27 to 3.19)
Vaccinated with BNT162b2	1,660,7 86	118,628	15	8.6	0.0004%	1.74 (1.05 to 2.89)
SARS-CoV-2 PCR positive test	299,175	40,593	5	1.8	0.0011%	2.83 (1.18 to 6.80)
Thrombocytopenia						
Vaccinated with ChAdOx1	1,840,4 95	117,121	1,707	1,368.00	0.0184%	1.25 (1.19 to 1.31)
Vaccinated with BNT162b2	1,632,3 28	116,491	1,462	1,477.10	-0.0009%	0.99 (0.94 to 1.04)
SARS-CoV-2 PCR positive test	296,999	40,289	254	248.6	0.0018%	1.02 (0.90 to 1.16)

VTE with thrombocytopenia						
Vaccinated with ChAdOx1	1,868,5 47	119,132	7	6.4	0.0000%	1.09 (0.52 to 2.29)
Vaccinated with BNT162b2	1,660,9 64	118,641	6	6.9	-0.0001%	0.86 (0.39 to 1.92)
ATE with thrombocytopenia						
Vaccinated with ChAdOx1	1,868,5 80	119,135	5	3.2	0.0001%	1.57 (0.65 to 3.78)
Stroke with thrombocytopenia						
Vaccinated with ChAdOx1	1,868,6 05	119,136	6	2.7	0.0002%	2.21 (0.99 to 4.91)

Figure 1. Distribution of age profiles and date of cohort entry among people vaccinated against SARS-CoV-2






Figure 2. Background and post-vaccine rates of thromboembolic events and thrombocytopenia by age and sex Events with less than 5 occurrences have been omitted for privacy reasons.





Figure 3. Expected versus observed events among those vaccinated against SARS-CoV-2 and those with a SARS-CoV-2 infection

Expected events for each of the study cohorts based on indirect standardization using rates from the general population between 2017 and 2019 are compared with the number of observed events seen in each cohort on the panels on the left. Corresponding standardized incidence ratios (SIRs) with 95% confidence intervals (95% CI) are shown in the panels on the right.



🛑 SARS-CoV-2 PCR positive test 📋 Vaccinated with BNT162b2 🛑 Vaccinated with ChAdOx1

Funding

This study was funded by the European Medicines Agency in the form of a competitive tender (Lot ROC No EMA/2017/09/PE). This document expresses the opinion of the authors of the paper, and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties. ER was supported by Instituto de Salud Carlos III (grant number CM20/00174). DPA is funded through a National Institute for Health Research (NIHR) Senior Research Fellowship (Grant number SRF-2018-11-ST2-004).

Ethical approvals

The protocol for this research was approved by the Independent Scientific Advisory Committee (ISAC) for MHRA Database Research (protocol number 20_000211).

Acknowledgements

This study was funded by the European Medicines Agency in the form of a competitive tender (Lot ROC No EMA/2017/09/PE). We acknowledge Prof Johan Van der Lei for the overall management of this research grant.

Declarations of interest

DPA's research group has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, from Amgen, Chiesi, and from UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen and UCB Biopharma.

Appendix

Patient characteristics by age group

Characteristics of study participants aged: 30 to 44

The characteristics of the study cohorts used for the primary analyses, all with the requirement to be aged 30 years or older and with a year of prior history observed in the database. Those in the general population had a primary care visit/ contact between 2017 and 2019 while persons infected with SARS-CoV-2 had a confirmatory positive RT-PCR test. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. [†]Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2	SARS-CoV-2 PCR positive test
Ν	644,372	202,865	217,319	121,692
Age	37 [33 to 41]	38 [34 to 41]	38 [34 to 41]	37 [33 to 41]
Age: 30 to 39	431,801 (67.0%)	123,991 (61.1%)	135,101 (62.2%)	82,427 (67.7%)
Age: 40 to 49	212,571 (33.0%)	78,874 (38.9%)	82,218 (37.8%)	39,265 (32.3%)
Sex: Male	306,045 (47.5%)	74,116 (36.5%)	70,735 (32.5%)	53,806 (44.2%)
Years of prior observation time	10.4 [4.8 to 14.9]	8.3 [4.1 to 15.9]	7.7 [3.8 to 14.9]	7.9 [3.8 to 15.7]
Comorbidities				
Autoimmune disease	8,875 (1.4%)	5,779 (2.8%)	5,283 (2.4%)	1,847 (1.5%)
Antiphospholipid syndrome	259 (0.0%)	273 (0.1%)	251 (0.1%)	76 (0.1%)
Thrombophilia	851 (0.1%)	660 (0.3%)	654 (0.3%)	227 (0.2%)
Asthma	102,513 (15.9%)	47,467 (23.4%)	46,382 (21.3%)	20,043 (16.5%)
Atrial fibrillation	927 (0.1%)	879 (0.4%)	863 (0.4%)	192 (0.2%)
Malignant neoplastic disease	7,288 (1.1%)	5,844 (2.9%)	5,492 (2.5%)	1,356 (1.1%)
Diabetes mellitus	17,185 (2.7%)	27,531 (13.6%)	19,860 (9.1%)	5,576 (4.6%)
Obesity	18,089 (2.8%)	13,635 (6.7%)	11,684 (5.4%)	4,815 (4.0%)
Heart disease	11,653 (1.8%)	10,509 (5.2%)	9,827 (4.5%)	2,886 (2.4%)
Hypertensive disorder	20,630 (3.2%)	13,490 (6.6%)	12,430 (5.7%)	4,910 (4.0%)

Renal impairment	4,449 (0.7%)	4,107 (2.0%)	3,695 (1.7%)	1,149 (0.9%)
COPD	929 (0.1%)	911 (0.4%)	613 (0.3%)	96 (0.1%)
Dementia	772 (0.1%)	738 (0.4%)	638 (0.3%)	206 (0.2%)
Medication use (183 days prior to				
four days prior)				
Non-steroidal anti-inflammatory	107,115 (16.6%)	20,685 (10.2%)	18,571 (8.5%)	9,204 (7.6%)
drugs				
Cox2 inhibitors	933 (0.1%)	183 (0.1%)	147 (0.1%)	54 (0.0%)
Systemic corticosteroids	44,535 (6.9%)	10,629 (5.2%)	9,351 (4.3%)	4,406 (3.6%)
Antithrombotic and anticoagulant	4,599 (0.7%)	1,031 (0.5%)	789 (0.4%)	269 (0.2%)
therapies				
Lipid modifying agents	4,098 (0.6%)	1,861 (0.9%)	1,543 (0.7%)	490 (0.4%)
Antineoplastic and	29,367 (4.6%)	5,402 (2.7%)	6,002 (2.8%)	2,591 (2.1%)
immunomodulating agents				
Hormonal contraceptives for systemic	50,360 (7.8%)	9,897 (4.9%)	11,305 (5.2%)	5,000 (4.1%)
use				
Tamoxifen	190 (0.0%)	47 (0.0%)	44 (0.0%)	14 (0.0%)
Sex hormones and modulators of the	52,721 (8.2%)	10,572 (5.2%)	11,987 (5.5%)	5,268 (4.3%)
genital system				
One or more condition of interest*	52,792 (8.2%)	50,913 (25.1%)	41,923 (19.3%)	13,637 (11.2%)
One or more medication of interest [†]	158,520 (24.6%)	33,547 (16.5%)	32,307 (14.9%)	15,456 (12.7%)
One or more condition/ medication of interest* [†]	191,069 (29.7%)	73,997 (36.5%)	65,853 (30.3%)	26,342 (21.6%)

Characteristics of study participants: aged 45 to 64

The characteristics of the study cohorts used for the primary analyses, all with the requirement to be aged 30 years or older and with a year of prior history observed in the database. Those in the general population had a primary care visit/ contact between 2017 and 2019 while persons infected with SARS-CoV-2 had a confirmatory positive RT-PCR test. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. [†]Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population			SARS-CoV-2 PCR positive test
Ν	963,696	624,698	534,049	138,195
Age	54 [49 to 59]	57 [52 to 62]	56 [51 to 60]	53 [49 to 58]
Age: 40 to 49	246,829 (25.6%)	94,579 (15.1%)	96,285 (18.0%)	37,919 (27.4%)
Age: 50 to 59	506,515 (52.6%)	285,938 (45.8%)	279,223 (52.3%)	75,543 (54.7%)
Age: 60 to 69	210,352 (21.8%)	244,181 (39.1%)	158,541 (29.7%)	24,733 (17.9%)
Age: 70 to 79	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Age: 80 or older	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sex: Male	476,832 (49.5%)	287,869 (46.1%)	215,350 (40.3%)	64,807 (46.9%)
Years of prior observation time	13.8 [9.4 to 16.5]	16.9 [7.5 to 27.0]	16.6 [7.6 to 26.4]	16.0 [7.4 to 25.3]
Comorbidities				
Autoimmune disease	22,807 (2.4%)	24,114 (3.9%)	20,452 (3.8%)	3,497 (2.5%)
Antiphospholipid syndrome	553 (0.1%)	785 (0.1%)	670 (0.1%)	125 (0.1%)
Thrombophilia	1,247 (0.1%)	1,721 (0.3%)	1,511 (0.3%)	284 (0.2%)
Asthma	120,450 (12.5%)	107,823 (17.3%)	94,363 (17.7%)	19,830 (14.3%)
Atrial fibrillation	10,190 (1.1%)	12,981 (2.1%)	12,425 (2.3%)	1,594 (1.2%)
Malignant neoplastic disease	49,036 (5.1%)	53,877 (8.6%)	47,018 (8.8%)	6,929 (5.0%)
Diabetes mellitus	70,192 (7.3%)	102,585 (16.4%)	90,441 (16.9%)	14,163 (10.2%)
Obesity	43,294 (4.5%)	48,229 (7.7%)	40,960 (7.7%)	9,226 (6.7%)
Heart disease	60,885 (6.3%)	73,169 (11.7%)	66,530 (12.5%)	9,890 (7.2%)
Hypertensive disorder	173,364 (18.0%)	164,162 (26.3%)	137,388 (25.7%)	28,262 (20.5%)

Renal impairment	26,427 (2.7%)	32,833 (5.3%)	28,361 (5.3%)	4,445 (3.2%)
COPD	21,130 (2.2%)	27,484 (4.4%)	20,039 (3.8%)	2,056 (1.5%)
Dementia	1,914 (0.2%)	2,642 (0.4%)	1,983 (0.4%)	370 (0.3%)
Medication use (183 days prior to				
four days prior)				
Non-steroidal anti-inflammatory	234,513 (24.3%)	79,342 (12.7%)	65,776 (12.3%)	15,556 (11.3%)
drugs				
Cox2 inhibitors	3,024 (0.3%)	793 (0.1%)	609 (0.1%)	161 (0.1%)
Systemic corticosteroids	97,185 (10.1%)	36,413 (5.8%)	29,039 (5.4%)	6,364 (4.6%)
Antithrombotic and anticoagulant	25,233 (2.6%)	12,124 (1.9%)	10,842 (2.0%)	1,489 (1.1%)
therapies				
Lipid modifying agents	47,616 (4.9%)	28,586 (4.6%)	24,220 (4.5%)	4,436 (3.2%)
Antineoplastic and	14,370 (1.5%)	5,635 (0.9%)	4,958 (0.9%)	874 (0.6%)
immunomodulating agents				
Hormonal contraceptives for	25,338 (2.6%)	7,644 (1.2%)	8,444 (1.6%)	2,172 (1.6%)
systemic use				
Tamoxifen	1,095 (0.1%)	449 (0.1%)	438 (0.1%)	61 (0.0%)
Sex hormones and modulators of	43,992 (4.6%)	19,408 (3.1%)	20,440 (3.8%)	4,542 (3.3%)
the genital system			105 178 (26 5%)	22.104 (24.0%)
One or more condition of interest*	187,548 (19.5%)	221,112 (35.4%)	195,178 (36.5%)	33,104 (24.0%)
One or more medication of	288,508 (29.9%)	108,882 (17.4%)	93,553 (17.5%)	21,648 (15.7%)
interest [†]				
One or more condition/	395,455 (41.0%)	283,344 (45.4%)	248,153 (46.5%)	47,564 (34.4%)
medication of interest*†				

Characteristics of study participants: age 65 or older

The characteristics of the study cohorts used for the primary analyses, all with the requirement to be aged 30 years or older and with a year of prior history observed in the database. Those in the general population had a primary care visit/ contact between 2017 and 2019 while persons infected with SARS-CoV-2 had a confirmatory positive RT-PCR test. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. [†]Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2	SARS-CoV-2 PCR positive test		
N	682,469	1,041,204	909,771	39,424		
Age	74 [69 to 80]	73 [69 to 77]	77 [71 to 83]	73 [68 to 80]		
Age: 60 to 69	193,321 (28.3%)	322,860 (31.0%)	163,711 (18.0%)	13,913 (35.3%)		
Age: 70 to 79	301,179 (44.1%)	545,251 (52.4%)	372,426 (40.9%)	14,839 (37.6%)		
Age: 80 or older	187,969 (27.5%)	173,093 (16.6%)	373,634 (41.1%)	10,672 (27.1%)		
Sex: Male	312,034 (45.7%)	483,923 (46.5%)	416,778 (45.8%)	17,688 (44.9%)		
Years of prior observation time	14.3 [12.2 to 17.3]	23.6 [10.1 to 34.6]	24.9 [11.4 to 35.6]	20.6 [6.8 to 32.8]		
Comorbidities						
Autoimmune disease	26,091 (3.8%)	42,226 (4.1%)	38,576 (4.2%)	1,792 (4.5%)		
Antiphospholipid syndrome	234 (0.0%)	477 (0.0%)	428 (0.0%)	14 (0.0%)		
Thrombophilia	484 (0.1%)	1,247 (0.1%)	1,027 (0.1%)	38 (0.1%)		
Asthma	78,706 (11.5%)	128,836 (12.4%)	112,432 (12.4%)	5,597 (14.2%)		
Atrial fibrillation	61,526 (9.0%)	86,870 (8.3%)	104,110 (11.4%)	4,207 (10.7%)		
Malignant neoplastic disease	131,175 (19.2%)	197,728 (19.0%)	216,145 (23.8%)	7,378 (18.7%)		
Diabetes mellitus	110,242 (16.2%)	176,828 (17.0%)	165,893 (18.2%)	8,749 (22.2%)		
Obesity	32,671 (4.8%)	58,188 (5.6%)	46,256 (5.1%)	2,750 (7.0%)		
Heart disease	179,170 (26.3%)	250,791 (24.1%)	273,312 (30.0%)	11,735 (29.8%)		
Hypertensive disorder	339,756 (49.8%)	500,091 (48.0%)	493,527 (54.2%)	20,749 (52.6%)		
Renal impairment	130,720 (19.2%)	170,811 (16.4%)	202,330 (22.2%)	8,556 (21.7%)		
COPD	55,146 (8.1%)	79,241 (7.6%)	75,002 (8.2%)	3,232 (8.2%)		

Dementia	26,690 (3.9%)	35,209 (3.4%)	32,208 (3.5%)	4,310 (10.9%)
Medication use (183 days prior to four days prior)				
Non-steroidal anti-inflammatory drugs	276,924 (40.6%)	164,063 (15.8%)	157,962 (17.4%)	8,539 (21.7%)
Cox2 inhibitors	2,158 (0.3%)	955 (0.1%)	825 (0.1%)	43 (0.1%)
Systemic corticosteroids	121,768 (17.8%)	72,724 (7.0%)	67,587 (7.4%)	3,398 (8.6%)
Antithrombotic and anticoagulant therapies	72,773 (10.7%)	48,167 (4.6%)	53,606 (5.9%)	2,127 (5.4%)
Lipid modifying agents	78,550 (11.5%)	79,882 (7.7%)	77,072 (8.5%)	3,298 (8.4%)
Antineoplastic and immunomodulating agents	13,666 (2.0%)	9,408 (0.9%)	9,581 (1.1%)	357 (0.9%)
Hormonal contraceptives for systemic use	1,098 (0.2%)	1,025 (0.1%)	742 (0.1%)	33 (0.1%)
Tamoxifen	672 (0.1%)	318 (0.0%)	317 (0.0%)	12 (0.0%)
Sex hormones and modulators of the genital system	13,870 (2.0%)	14,632 (1.4%)	12,136 (1.3%)	473 (1.2%)
One or more condition of interest*	339,288 (49.7%)	506,534 (48.6%)	514,123 (56.5%)	22,138 (56.2%)
One or more medication of interest [†]	311,320 (45.6%)	203,446 (19.5%)	192,844 (21.2%)	10,135 (25.7%)
One or more condition/ medication of interest* [†]	471,617 (69.1%)	591,852 (56.8%)	583,751 (64.2%)	25,821 (65.5%)

Results for all study outcomes

For each event of interest the number of persons contributing to the analysis from the target population, their person-years contributed, and the number of events observed for them are given. Their expected events are estimated using indirect standardisation to the general population, with expected events giving the number of events we would have expected to have seen if their outcome experience was the same as that of the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with less than 5 occurrences have been omitted for privacy reasons. *Cerebral venous sinus thrombosis is reported without the requirement for a year of prior history as less than 5 events were seen when this restriction was imposed.

Front	Cabart		Person-	Observed	Expected	
Event	Cohort	Ν	years	events	events	SIR (95% CI)
	Vaccinated with	1,956,				2.32 (0.97 to
Cerebral venous sinus thrombosis*	ChAdOx1	136	124,569	5	2.2	5.58)
	Vaccinated with	1,862,				1.08 (0.96 to
Deep vein thrombosis - broad	ChAdOx1	896	118,757	275	255.1	1.21)
	Vaccinated with	1,656,				1.10 (0.99 to
Deep vein thrombosis - broad	BNT162b2	235	118,297	296	268.1	1.24)
	SARS-CoV-2 PCR	298,70				2.69 (2.28 to
Deep vein thrombosis - broad	positive test	7	40,517	143	53.2	3.17)
	Vaccinated with	1,863,				0.95 (0.83 to
Deep vein thrombosis - narrow	ChAdOx1	668	118,809	226	237.9	1.08)
	Vaccinated with	1,656,				1.01 (0.89 to
Deep vein thrombosis - narrow	BNT162b2	875	118,344	254	251.3	1.14)
	SARS-CoV-2 PCR	298,77				2.56 (2.15 to
Deep vein thrombosis - narrow	positive test	6	40,528	125	48.8	3.05)
Deep vein thrombosis broad with thrombocytopenia 10 days pre to	Vaccinated with	1,868,				1.45 (0.65 to
10 days post	ChAdOx1	584	119,135	6	4.1	3.23)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to	Vaccinated with	1,868,				1.22 (0.64 to
14 days post	ChAdOx1	547	119,132	9	7.4	2.35)
Deep vein thrombosis narrow with thrombocytopenia 42 days pre	Vaccinated with	1,868,				1.00 (0.48 to
to 14 days post	ChAdOx1	554	119,133	7	7	2.11)

	Vaccinated with	1,867,				1.04 (0.78 to
Hemorrhagic stroke	ChAdOx1	822	119,084	45	43.1	1.40)
	Vaccinated with	1,660,				0.81 (0.59 to
Hemorrhagic stroke	BNT162b2	431	118,603	38	46.8	1.12)
	SARS-CoV-2 PCR	299,12				1.34 (0.74 to
Hemorrhagic stroke	positive test	7	40,584	11	8.2	2.42)
	Vaccinated with	1,868,				2.01 (1.27 to
Immune thrombocytopenia	ChAdOx1	376	119,120	18	8.9	3.19)
	Vaccinated with	1,660,				1.74 (1.05 to
Immune thrombocytopenia	BNT162b2	786	118,628	15	8.6	2.89)
	SARS-CoV-2 PCR	299,17				2.83 (1.18 to
Immune thrombocytopenia	positive test	5	40,593	5	1.8	6.80)
	Vaccinated with	1,868,				0.86 (0.50 to
Intestinal infarction	ChAdOx1	365	119,120	13	15.1	1.48)
	Vaccinated with	1,660,				1.10 (0.68 to
Intestinal infarction	BNT162b2	825	118,631	17	15.5	1.77)
	Vaccinated with	1,867,				0.75 (0.60 to
Ischemic stroke	ChAdOx1	000	119,025	72	95.8	0.95)
	Vaccinated with	1,659,				1.11 (0.92 to
Ischemic stroke	BNT162b2	635	118,542	120	108.5	1.32)
	SARS-CoV-2 PCR	299,10				1.05 (0.61 to
Ischemic stroke	positive test	0	40,582	13	12.3	1.81)
	Vaccinated with	1,861,				0.84 (0.76 to
Myocardial infarction	ChAdOx1	365	118,643	347	411.3	0.94)
	Vaccinated with	1,654,				0.82 (0.74 to
Myocardial infarction	BNT162b2	037	118,145	356	433.4	0.91)
	SARS-CoV-2 PCR	298,63				1.20 (0.96 to
Myocardial infarction	positive test	2	40,509	79	65.7	1.50)
	Vaccinated with	1,858,				0.81 (0.73 to
Myocardial infarction or ischemic stroke	ChAdOx1	974	118,481	406	503.7	0.89)
	Vaccinated with	1,651,				0.85 (0.78 to
Myocardial infarction or ischemic stroke	BNT162b2	903	117,990	458	538.3	0.93)

	SARS-CoV-2 PCR	298,46				1.13 (0.92 to
Myocardial infarction or ischemic stroke	positive test	4	40,485	88	77.6	1.40)
Myocardial infarction or ischemic stroke with thrombocytopenia 10	Vaccinated with	1,868,				1.57 (0.65 to
days pre to 10 days post	ChAdOx1	580	119,135	5	3.2	3.78)
Myocardial infarction or ischemic stroke with thrombocytopenia 42	Vaccinated with	1,868,				1.53 (0.82 to
days pre to 14 days post	ChAdOx1	524	119,131	10	6.5	2.84)
Myocardial infarction or ischemic stroke with thrombocytopenia 42	Vaccinated with	1,660,				0.72 (0.32 to
days pre to 14 days post	BNT162b2	931	118,639	6	8.3	1.61)
	Vaccinated with	1,865,				2.29 (1.99 to
Platelet disorder	ChAdOx1	323	118,905	198	86.6	2.63)
	Vaccinated with	1,657,				1.98 (1.70 to
Platelet disorder	BNT162b2	943	118,416	174	88.1	2.29)
	SARS-CoV-2 PCR	298,92				3.60 (2.77 to
Platelet disorder	positive test	2	40,552	57	15.9	4.66)
	Vaccinated with	1,868,				1.48 (0.74 to
Portal vein thrombosis	ChAdOx1	539	119,133	8	5.4	2.95)
	Vaccinated with	1,863,				1.23 (1.09 to
Pulmonary embolism	ChAdOx1	403	118,787	259	210.4	1.39)
	Vaccinated with	1,656,				1.21 (1.07 to
Pulmonary embolism	BNT162b2	755	118,336	261	216.4	1.36)
	SARS-CoV-2 PCR	298,78				15.31 (14.08 to
Pulmonary embolism	positive test	6	40,491	547	35.7	16.65)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	Vaccinated with	1,868,				1.09 (0.49 to
days post	ChAdOx1	576	119,134	6	5.5	2.43)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	Vaccinated with	1,660,				1.18 (0.56 to
days post	BNT162b2	999	118,644	7	5.9	2.48)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	SARS-CoV-2 PCR	299,20				8.25 (3.71 to
days post	positive test	8	40,596	6	0.7	18.37)
	Vaccinated with	1,868,				1.38 (0.72 to
Splanchnic Vein Thrombosis	ChAdOx1	536	119,132	9	6.5	2.66)
	Vaccinated with	1,861,				1.02 (0.93 to
Stroke	ChAdOx1	358	118,629	413	405	1.12)

	Vaccinated with	1,654,				1.01 (0.92 to
Stroke	BNT162b2	569	118,167	457	454	1.10)
	SARS-CoV-2 PCR	298,70				1.19 (0.93 to
Stroke	positive test	9	40,525	65	54.5	1.52)
	Vaccinated with	1,868,				2.21 (0.99 to
Stroke with thrombocytopenia 10 days pre to 10 days post	ChAdOx1	605	119,136	6	2.7	4.91)
	Vaccinated with	1,868,				1.03 (0.46 to
Stroke with thrombocytopenia 42 days pre to 14 days post	ChAdOx1	573	119,134	6	5.8	2.29)
	Vaccinated with	1,660,				1.16 (0.58 to
Stroke with thrombocytopenia 42 days pre to 14 days post	BNT162b2	982	118,643	8	6.9	2.32)
	Vaccinated with	1,840,				1.25 (1.19 to
Thrombocytopenia	ChAdOx1	495	117,121	1,707	1,368.00	1.31)
	Vaccinated with	1,632,				0.99 (0.94 to
Thrombocytopenia	BNT162b2	328	116,491	1,462	1,477.10	1.04)
	SARS-CoV-2 PCR	296,99				1.02 (0.90 to
Thrombocytopenia	positive test	9	40,289	254	248.6	1.16)
	Vaccinated with	1,868,				1.49 (0.85 to
Thrombocytopenic purpura	ChAdOx1	562	119,134	12	8	2.63)
	Vaccinated with	1,660,				0.64 (0.26 to
Thrombocytopenic purpura	BNT162b2	955	118,641	5	7.9	1.53)
	Vaccinated with	1,858,				1.14 (1.05 to
Venous thromboembolism - broad	ChAdOx1	064	118,431	508	445.4	1.24)
	Vaccinated with	1,652,				1.15 (1.05 to
Venous thromboembolism - broad	BNT162b2	244	118,007	532	464.6	1.25)
	SARS-CoV-2 PCR	298,32				7.89 (7.31 to
Venous thromboembolism - broad	positive test	9	40,418	664	84.2	8.51)
	Vaccinated with	1,858,				1.07 (0.98 to
Venous thromboembolism - narrow	ChAdOx1	837	118,483	461	429.2	1.18)
	Vaccinated with	1,652,				1.09 (1.00 to
Venous thromboembolism - narrow	BNT162b2	892	118,054	491	448.6	
	SARS-CoV-2 PCR	298,39				8.08 (7.48 to
Venous thromboembolism - narrow	positive test	7	40,429	646	80	8.72)

Venous thromboembolism broad with thrombocytopenia 10 days	Vaccinated with	1,868,				1.35 (0.70 to
pre to 10 days post	ChAdOx1	543	119,132	9	6.7	2.60)
Venous thromboembolism broad with thrombocytopenia 10 days	Vaccinated with	1,660,				0.84 (0.38 to
pre to 10 days post	BNT162b2	959	118,641	6	7.1	1.87)
Venous thromboembolism broad with thrombocytopenia 42 days	Vaccinated with	1,868,				1.13 (0.67 to
pre to 14 days post	ChAdOx1	467	119,126	14	12.3	1.92)
Venous thromboembolism broad with thrombocytopenia 42 days	Vaccinated with	1,660,				0.75 (0.41 to
pre to 14 days post	BNT162b2	896	118,636	10	13.3	1.40)
Venous thromboembolism broad with thrombocytopenia 42 days	SARS-CoV-2 PCR	299,19				3.56 (1.60 to
pre to 14 days post	positive test	9	40,595	6	1.7	7.93)
Venous thromboembolism narrow with thrombocytopenia 10 days	Vaccinated with	1,868,				1.09 (0.52 to
pre to 10 days post	ChAdOx1	547	119,132	7	6.4	2.29)
Venous thromboembolism narrow with thrombocytopenia 10 days	Vaccinated with	1,660,				0.86 (0.39 to
pre to 10 days post	BNT162b2	964	118,641	6	6.9	1.92)
Venous thromboembolism narrow with thrombocytopenia 42 days	Vaccinated with	1,868,				1.00 (0.57 to
pre to 14 days post	ChAdOx1	472	119,127	12	12	1.76)
Venous thromboembolism narrow with thrombocytopenia 42 days	Vaccinated with	1,660,				0.77 (0.42 to
pre to 14 days post	BNT162b2	903	118,637	10	13	1.44)
Venous thromboembolism narrow with thrombocytopenia 42 days	SARS-CoV-2 PCR	299,19				3.72 (1.67 to
pre to 14 days post	positive test	9	40,595	6	1.6	8.29)

Results for vaccinated stratified by calendar month

For each event of interest the number of persons contributing to the analysis from the target population, their person-years contributed, and the number of events observed for them are given. Their expected events are estimated using indirect standardisation to the general population, with expected events giving the number of events we would have expected to have seen if their outcome experience was the same as that of the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with less than 5 occurrences have been omitted for privacy reasons.

Event	Cohort	Month	N	Person- years	Observed events	Expected events	SIR (95% CI)
	Vaccinated with	Januar	500,67				1.20 (1.00 to
Deep vein thrombosis - broad	ChAdOx1	у	0	38,273	120	100.4	1.43)
	Vaccinated with	Februa	1,057,				1.01 (0.86 to
Deep vein thrombosis - broad	ChAdOx1	ry	526	72,316	144	143	1.19)
	Vaccinated with	Decem	184,51				1.17 (0.88 to
Deep vein thrombosis - broad	BNT162b2	ber	9	14,132	48	41	1.55)
	Vaccinated with	Januar	821,95				1.13 (0.97 to
Deep vein thrombosis - broad	BNT162b2	у	2	62,905	176	155.9	1.31)
	Vaccinated with	Februa	634,70				0.99 (0.79 to
Deep vein thrombosis - broad	BNT162b2	ry	2	40,831	70	70.4	1.26)
	Vaccinated with	Januar	500,89				1.05 (0.86 to
Deep vein thrombosis - narrow	ChAdOx1	у	6	38,291	99	94.6	1.27)
	Vaccinated with	Februa	1,057,				0.90 (0.75 to
Deep vein thrombosis - narrow	ChAdOx1	ry	960	72,347	119	132.5	1.07)
	Vaccinated with	Decem	184,57				0.98 (0.71 to
Deep vein thrombosis - narrow	BNT162b2	ber	7	14,137	38	38.9	1.34)
	Vaccinated with	Januar	822,27				1.06 (0.91 to
Deep vein thrombosis - narrow	BNT162b2	у	2	62,930	156	146.8	1.24)
	Vaccinated with	Februa	634,96				0.90 (0.69 to
Deep vein thrombosis - narrow	BNT162b2	ry	0	40,848	58	64.8	1.16)
Deep vein thrombosis broad with thrombocytopenia 42 days pre	Vaccinated with	Februa	1,060,				1.27 (0.53 to
to 14 days post	ChAdOx1	ry	631	72,536	5	3.9	3.04)

	Vaccinated with	Januar	502,16				1.30 (0.86 to
Hemorrhagic stroke	ChAdOx1	y	0	38,389	23	17.7	1.96)
	Vaccinated with	Februa	1,060,				0.94 (0.62 to
Hemorrhagic stroke	ChAdOx1	ry	241	72,509	22	23.5	1.42)
	Vaccinated with	Decem	184,97				1.17 (0.61 to
Hemorrhagic stroke	BNT162b2	ber	6	14,169	9	7.7	2.25)
	Vaccinated with	Januar	823,97				0.72 (0.47 to
Hemorrhagic stroke	BNT162b2	у	7	63,066	20	27.6	1.12)
	Vaccinated with	Februa	636,38				0.79 (0.41 to
Hemorrhagic stroke	BNT162b2	ry	4	40,939	9	11.4	1.52)
	Vaccinated with	Januar	502,32				2.68 (1.39 to
Immune thrombocytopenia	ChAdOx1	у	6	38,402	9	3.4	5.15)
	Vaccinated with	Februa	1,060,				1.73 (0.90 to
Immune thrombocytopenia	ChAdOx1	ry	537	72,529	9	5.2	3.33)
	Vaccinated with	Januar	824,13				2.81 (1.67 to
Immune thrombocytopenia	BNT162b2	у	0	63,078	14	5	4.75)
	Vaccinated with	Januar	502,33				1.46 (0.76 to
Intestinal infarction	ChAdOx1	у	7	38,403	9	6.2	2.81)
	Vaccinated with	Januar	824,16				1.31 (0.74 to
Intestinal infarction	BNT162b2	у	1	63,080	12	9.2	2.30)
	Vaccinated with	Januar	501,80				0.86 (0.62 to
Ischemic stroke	ChAdOx1	у	3	38,361	37	43.1	1.18)
	Vaccinated with	Februa	1,059,				0.69 (0.49 to
Ischemic stroke	ChAdOx1	ry	837	72,479	34	49.6	0.96)
	Vaccinated with	Decem	184,82				1.31 (0.89 to
Ischemic stroke	BNT162b2	ber	4	14,157	26	19.9	1.92)
	Vaccinated with	Januar	823,54				1.02 (0.81 to
Ischemic stroke	BNT162b2	у	0	63,031	68	66.4	1.30)
	Vaccinated with	Februa	636,18				1.18 (0.81 to
Ischemic stroke	BNT162b2	ry	9	40,926	26	22	1.74)
	Vaccinated with	Januar	500,16				0.85 (0.72 to
Myocardial infarction	ChAdOx1	у	5	38,233	140	164.6	1.00)

	Vaccinated with	Februa	1,056,				0.86 (0.75 to
Myocardial infarction	ChAdOx1	ry	556	72,245	198	229	0.99)
	Vaccinated with	, Decem	184,25	,			0.71 (0.53 to
Myocardial infarction	BNT162b2	ber	5	14,112	49	69.3	0.94)
	Vaccinated with	Januar	821,18				0.78 (0.67 to
Myocardial infarction	BNT162b2	у	2	62,846	196	252.8	0.89)
	Vaccinated with	Februa	633,56				1.00 (0.83 to
Myocardial infarction	BNT162b2	ry	8	40,760	110	110.1	1.20)
	Vaccinated with	Januar	499,33				0.82 (0.71 to
Myocardial infarction or ischemic stroke	ChAdOx1	у	3	38,168	170	206.2	0.96)
	Vaccinated with	Februa	1,055,				0.82 (0.72 to
Myocardial infarction or ischemic stroke	ChAdOx1	ry	276	72,154	226	276.8	0.93)
	Vaccinated with	Decem	183,92				0.82 (0.66 to
Myocardial infarction or ischemic stroke	BNT162b2	ber	1	14,086	73	88.5	1.04)
	Vaccinated with	Januar	820,11				0.81 (0.71 to
Myocardial infarction or ischemic stroke	BNT162b2	у	0	62,762	256	317	0.91)
	Vaccinated with	Februa	632,86				0.98 (0.83 to
Myocardial infarction or ischemic stroke	BNT162b2	ry	3	40,715	129	131.2	1.17)
Myocardial infarction or ischemic stroke with thrombocytopenia	Vaccinated with	Januar	502,37				1.51 (0.63 to
42 days pre to 14 days post	ChAdOx1	у	6	38,406	5	3.3	3.63)
Myocardial infarction or ischemic stroke with thrombocytopenia	Vaccinated with	Februa	1,060,				1.63 (0.68 to
42 days pre to 14 days post	ChAdOx1	ry	624	72,535	5	3.1	3.92)
	Vaccinated with	Januar	501,27				2.37 (1.91 to
Platelet disorder	ChAdOx1	у	8	38,320	80	33.7	2.96)
	Vaccinated with	Februa	1,058,				2.22 (1.84 to
Platelet disorder	ChAdOx1	ry	821	72,404	109	49.1	2.68)
	Vaccinated with	Decem	184,63				1.54 (1.00 to
Platelet disorder	BNT162b2	ber	7	14,143	20	13	2.39)
	Vaccinated with	Januar	822,62				2.15 (1.78 to
Platelet disorder	BNT162b2	у	3	62,959	110	51.2	2.59)
	Vaccinated with	Februa	635,60				1.77 (1.31 to
Platelet disorder	BNT162b2	ry	5	40,885	42	23.7	2.40)

	Vaccinated with	Februa	1,060,				1.53 (0.64 to
Portal vein thrombosis	ChAdOx1	ry	619	72,535	5	33	3.68)
	Vaccinated with	Januar	500,83	, 2,000		0.0	1.33 (1.10 to
Pulmonary embolism	ChAdOx1	v	7	38,285	111	83.6	1.60)
	Vaccinated with	Februa	1,057,				1.19 (1.01 to
Pulmonary embolism	ChAdOx1	ry	749	72,331	141	118	1.41)
	Vaccinated with	, Decem	184,57	,			0.94 (0.66 to
Pulmonary embolism	BNT162b2	ber	3	14,137	31	32.9	1.34)
	Vaccinated with	Januar	822,27	·			1.25 (1.07 to
Pulmonary embolism	BNT162b2	y	9	62,931	159	126.8	1.46)
	Vaccinated with	Februa	634,85				1.21 (0.96 to
Pulmonary embolism	BNT162b2	ry	0	40,840	68	56.1	1.54)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	Vaccinated with	Januar	824,23				1.37 (0.57 to
days post	BNT162b2	у	8	63,086	5	3.6	3.30)
	Vaccinated with	Februa	1,060,				1.28 (0.53 to
Splanchnic Vein Thrombosis	ChAdOx1	ry	615	72,535	5	3.9	3.07)
	Vaccinated with	Januar	499,55				1.12 (0.98 to
Stroke	ChAdOx1	у	5	38,185	201	179.2	1.29)
	Vaccinated with	Februa	1,056,				0.99 (0.86 to
Stroke	ChAdOx1	ry	990	72,274	209	212.1	1.13)
	Vaccinated with	Decem	184,05				1.09 (0.89 to
Stroke	BNT162b2	ber	9	14,096	89	81.5	1.34)
	Vaccinated with	Januar	820,89				0.91 (0.80 to
Stroke	BNT162b2	у	9	62,823	250	276.1	1.02)
	Vaccinated with	Februa	634,57				1.22 (1.02 to
Stroke	BNT162b2	ry	8	40,821	116	95.1	1.46)
	Vaccinated with	Januar	824,23				1.61 (0.77 to
Stroke with thrombocytopenia 42 days pre to 14 days post	BNT162b2	у	3	63,086	7	4.4	3.37)
	Vaccinated with	Januar	491,13				1.28 (1.19 to
Thrombocytopenia	ChAdOx1	у	2	37,523	722	564.8	,
	Vaccinated with	Februa	1,046,				1.22 (1.14 to
Thrombocytopenia	ChAdOx1	ry	181	71,473	908	746.5	1.30)

	Vaccinated with	Decem	180,47				0.70 (0.60 to
Thrombocytopenia	BNT162b2	ber	5	13,819	170	242.4	0.82)
	Vaccinated with	Januar	808,02				1.02 (0.96 to
Thrombocytopenia	BNT162b2	у	9	61,815	897	875.2	1.09)
	Vaccinated with	Februa	628,92				1.10 (0.99 to
Thrombocytopenia	BNT162b2	ry	8	40,433	389	355.1	1.21)
	Vaccinated with	Januar	502,39				2.32 (1.11 to
Thrombocytopenic purpura	ChAdOx1	у	2	38,407	7	3	4.87)
	Vaccinated with	Februa	1,060,				1.07 (0.45 to
Thrombocytopenic purpura	ChAdOx1	ry	648	72,537	5	4.7	2.58)
	Vaccinated with	Januar	824,22				1.10 (0.46 to
Thrombocytopenic purpura	BNT162b2	у	5	63,085	5	4.5	2.65)
	Vaccinated with	Januar	499,19				1.22 (1.07 to
Venous thromboembolism - broad	ChAdOx1	у	7	38,157	216	176.9	1.40)
	Vaccinated with	Februa	1,054,				1.10 (0.98 to
Venous thromboembolism - broad	ChAdOx1	ry	809	72,122	275	249.1	1.24)
	Vaccinated with	Decem	184,05				1.09 (0.88 to
Venous thromboembolism - broad	BNT162b2	ber	4	14,096	78	71.2	1.37)
	Vaccinated with	Januar	820,09				1.18 (1.06 to
Venous thromboembolism - broad	BNT162b2	у	6	62,758	320	271.7	1.31)
	Vaccinated with	Februa	633,07				1.08 (0.91 to
Venous thromboembolism - broad	BNT162b2	ry	4	40,726	130	120.3	1.28)
	Vaccinated with	Januar	499,41				1.14 (0.99 to
Venous thromboembolism - narrow	ChAdOx1	у	9	38,175	196	171.4	1.32)
	Vaccinated with	Februa	1,055,				1.05 (0.93 to
Venous thromboembolism - narrow	ChAdOx1	ry	248	72,154	251	239.3	1.19)
	Vaccinated with	Decem	184,11				0.98 (0.78 to
Venous thromboembolism - narrow	BNT162b2	ber	2	14,100	68	69.2	1.25)
	Vaccinated with	Januar	820,42				1.14 (1.02 to
Venous thromboembolism - narrow	BNT162b2	у	0	62,783	301	263	1.28)
	Vaccinated with	Februa	633,33				1.03 (0.86 to
Venous thromboembolism - narrow	BNT162b2	ry	5	40,743	118	115	1.23)

Venous thromboembolism broad with thrombocytopenia 10	Vaccinated with	Februa	1,060,				1.39 (0.58 to
days pre to 10 days post	ChAdOx1	ry	628	72,536	5	3.6	3.33)
Venous thromboembolism broad with thrombocytopenia 42	Vaccinated with	Januar	502,35				1.11 (0.50 to
days pre to 14 days post	ChAdOx1	у	2	38,404	6	5.4	2.47)
Venous thromboembolism broad with thrombocytopenia 42	Vaccinated with	Februa	1,060,				1.22 (0.61 to
days pre to 14 days post	ChAdOx1	ry	591	72,533	8	6.6	2.44)
Venous thromboembolism broad with thrombocytopenia 42	Vaccinated with	Januar	824,17				0.86 (0.41 to
days pre to 14 days post	BNT162b2	у	1	63,081	7	8.1	1.81)
Venous thromboembolism narrow with thrombocytopenia 42	Vaccinated with	Januar	502,35				1.14 (0.51 to
days pre to 14 days post	ChAdOx1	у	3	38,404	6	5.3	2.53)
Venous thromboembolism narrow with thrombocytopenia 42	Vaccinated with	Februa	1,060,				0.95 (0.43 to
days pre to 14 days post	ChAdOx1	ry	595	72,533	6	6.3	2.11)
Venous thromboembolism narrow with thrombocytopenia 42	Vaccinated with	Januar	824,17				0.88 (0.42 to
days pre to 14 days post	BNT162b2	у	7	63,081	7	7.9	1.85)

Results without requiring year of prior history

For each event of interest the number of persons contributing to the analysis from the target population, their person-years contributed, and the number of events observed for them are given. Their expected events are estimated using indirect standardisation to the general population, with expected events giving the number of events we would have expected to have seen if their outcome experience was the same as that of the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with less than 5 occurrences have been omitted for privacy reasons.

Event	Cohort	N	Person- years	Observed events	Expected events	SIR (95% CI)
	Vaccinated with	1,956,				2.32 (0.97 to
Cerebral venous sinus thrombosis	ChAdOx1	136	124,569	5	2.2	5.58)
	Vaccinated with	1,950,				1.11 (0.99 to
Deep vein thrombosis - broad	ChAdOx1	188	124,172	305	275.8	1.24)
	Vaccinated with	1,726,				1.08 (0.96 to
Deep vein thrombosis - broad	BNT162b2	968	123,253	312	289.5	1.20)
	SARS-CoV-2 PCR	298,83				2.60 (2.20 to
Deep vein thrombosis - broad	positive test	2	40,538	143	55.1	3.06)
	Vaccinated with	1,950,				0.98 (0.87 to
Deep vein thrombosis - narrow	ChAdOx1	982	124,225	253	258	1.11)
	Vaccinated with	1,727,				0.98 (0.87 to
Deep vein thrombosis - narrow	BNT162b2	622	123,301	268	272.3	1.11)
	SARS-CoV-2 PCR	298,90				2.46 (2.07 to
Deep vein thrombosis - narrow	positive test	1	40,549	125	50.8	2.93)
Deep vein thrombosis broad with thrombocytopenia 10 days pre to	Vaccinated with	1,956,				1.96 (1.02 to
10 days post	ChAdOx1	124	124,567	9	4.6	3.77)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to	Vaccinated with	1,956,				1.51 (0.86 to
14 days post	ChAdOx1	087	124,564	12	8	2.65)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to	Vaccinated with	1,731,				0.59 (0.25 to
14 days post	BNT162b2	862	123,610	5	8.4	1.42)
Deep vein thrombosis narrow with thrombocytopenia 10 days pre	Vaccinated with	1,956,				1.39 (0.62 to
to 10 days post	ChAdOx1	131	124,568	6	4.3	3.09)

Deep vein thrombosis narrow with thrombocytopenia 42 days pre	Vaccinated with	1,956,				1.19 (0.62 to
to 14 days post	ChAdOx1	096	124,565	9	7.6	2.29)
Deep vein thrombosis narrow with thrombocytopenia 42 days pre	Vaccinated with	1,731,				0.62 (0.26 to
to 14 days post	BNT162b2	870	123,610	5	8.1	1.48)
	Vaccinated with	1,955,				1.08 (0.82 to
Hemorrhagic stroke	ChAdOx1	323	124,513	51	47.2	1.42)
	Vaccinated with	1,731,				0.74 (0.54 to
Hemorrhagic stroke	BNT162b2	304	123,569	38	51.3	1.02)
	SARS-CoV-2 PCR	299,25				1.29 (0.71 to
Hemorrhagic stroke	positive test	2	40,605	11	8.5	2.33)
	Vaccinated with	1,955,				1.82 (1.14 to
Immune thrombocytopenia	ChAdOx1	913	124,552	18	9.9	2.88)
	Vaccinated with	1,731,				1.68 (1.03 to
Immune thrombocytopenia	BNT162b2	680	123,596	16	9.5	2.75)
	SARS-CoV-2 PCR	299,30				2.71 (1.13 to
Immune thrombocytopenia	positive test	0	40,614	5	1.8	6.52)
	Vaccinated with	1,955,				1.01 (0.62 to
Intestinal infarction	ChAdOx1	897	124,551	16	15.8	1.66)
	Vaccinated with	1,731,				1.12 (0.71 to
Intestinal infarction	BNT162b2	725	123,600	18	16	1.78)
	Vaccinated with	1,954,				0.81 (0.65 to
Ischemic stroke	ChAdOx1	444	124,451	83	103.1	1.00)
	Vaccinated with	1,730,				1.07 (0.90 to
Ischemic stroke	BNT162b2	486	123,507	124	115.7	1.28)
	SARS-CoV-2 PCR	299,22				1.03 (0.60 to
Ischemic stroke	positive test	5	40,603	13	12.6	1.77)
	Vaccinated with	1,948,				0.84 (0.75 to
Myocardial infarction	ChAdOx1	615	124,056	368	440.2	0.93)
	Vaccinated with	1,724,				0.82 (0.74 to
Myocardial infarction	BNT162b2	692	123,097	375	459	0.90)
	SARS-CoV-2 PCR	298,75				1.17 (0.94 to
Myocardial infarction	positive test	7	40,530	79	67.2	1.46)

	Vaccinated with	1,946,				0.81 (0.74 to
Myocardial infarction or ischemic stroke	ChAdOx1	125	123,887	438	539.6	``
	Vaccinated with	1,722,	,			0.84 (0.77 to
Myocardial infarction or ischemic stroke	BNT162b2	509	122,937	481	570.7	•
· ·	SARS-CoV-2 PCR	298,58				1.11 (0.90 to
Myocardial infarction or ischemic stroke	positive test	9	40,506	88	79.4	1.37)
Myocardial infarction or ischemic stroke with thrombocytopenia 10	Vaccinated with	1,956,				1.39 (0.58 to
days pre to 10 days post	ChAdOx1	120	124,567	5	3.6	3.34)
Myocardial infarction or ischemic stroke with thrombocytopenia 10	Vaccinated with	1,731,				1.12 (0.47 to
days pre to 10 days post	BNT162b2	873	123,611	5	4.5	2.69)
Myocardial infarction or ischemic stroke with thrombocytopenia 42	Vaccinated with	1,956,				1.39 (0.75 to
days pre to 14 days post	ChAdOx1	063	124,563	10	7.2	2.58)
Myocardial infarction or ischemic stroke with thrombocytopenia 42	Vaccinated with	1,731,				0.80 (0.38 to
days pre to 14 days post	BNT162b2	829	123,607	7	8.8	1.67)
	Vaccinated with	1,952,				2.29 (2.00 to
Platelet disorder	ChAdOx1	742	124,328	216	94.4	2.62)
	Vaccinated with	1,728,				1.93 (1.67 to
Platelet disorder	BNT162b2	759	123,378	184	95.6	2.22)
	SARS-CoV-2 PCR	299,04				3.40 (2.62 to
Platelet disorder	positive test	7	40,574	57	16.8	4.41)
	Vaccinated with	1,956,				1.41 (0.71 to
Portal vein thrombosis	ChAdOx1	077	124,565	8	5.7	2.82)
	Vaccinated with	1,950,				1.24 (1.11 to
Pulmonary embolism	ChAdOx1	701	124,202	281	225.9	1.40)
	Vaccinated with	1,727,				1.22 (1.09 to
Pulmonary embolism	BNT162b2	494	123,293	282	231.3	,
	SARS-CoV-2 PCR	298,91				14.77 (13.58 to
Pulmonary embolism	positive test	0	40,513	547	37	16.06)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	Vaccinated with	1,956,				1.02 (0.46 to
days post	ChAdOx1	118	124,567	6	5.9	2.26)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	Vaccinated with	1,731,				1.15 (0.55 to
days post	BNT162b2	900	123,612	7	6.1	2.40)

Pulmonary embolism with thrombocytopenia 42 days pre to 14	SARS-CoV-2 PCR	299,33				7.96 (3.58 to
days post	positive test	3	40,618	6	0.8	17.71)
	Vaccinated with	1,956,				1.31 (0.68 to
Splanchnic Vein Thrombosis	ChAdOx1	072	124,564	9	6.9	2.52)
	Vaccinated with	1,948,				1.09 (0.99 to
Stroke	ChAdOx1	412	124,026	481	443	1.19)
	Vaccinated with	1,725,				0.97 (0.89 to
Stroke	BNT162b2	125	123,110	482	495.6	1.06)
	SARS-CoV-2 PCR	298,83				1.16 (0.91 to
Stroke	positive test	4	40,547	66	56.9	1.48)
	Vaccinated with	1,956,				1.88 (0.85 to
Stroke with thrombocytopenia 10 days pre to 10 days post	ChAdOx1	146	124,568	6	3.2	4.19)
	Vaccinated with	1,956,				1.07 (0.51 to
Stroke with thrombocytopenia 42 days pre to 14 days post	ChAdOx1	114	124,566	7	6.5	2.25)
	Vaccinated with	1,731,				1.04 (0.52 to
Stroke with thrombocytopenia 42 days pre to 14 days post	BNT162b2	882	123,611	8	7.7	2.09)
	Vaccinated with	1,927,				1.23 (1.17 to
Thrombocytopenia	ChAdOx1	116	122,484	1,865	1,517.30	1.29)
	Vaccinated with	1,702,				0.95 (0.91 to
Thrombocytopenia	BNT162b2	494	121,405	1,548	1,624.40	1.00)
	SARS-CoV-2 PCR	297,12				0.95 (0.84 to
Thrombocytopenia	positive test	2	40,310	254	266.7	1.08)
	Vaccinated with	1,956,				1.31 (0.74 to
Thrombocytopenic purpura	ChAdOx1	098	124,565	12	9.2	2.31)
	Vaccinated with	1,731,				0.68 (0.30 to
Thrombocytopenic purpura	BNT162b2	847	123,609	6	8.9	1.51)
	Vaccinated with	1,945,				1.16 (1.07 to
Venous thromboembolism - broad	ChAdOx1	125	123,830	558	479.9	1.26)
	Vaccinated with	1,722,				1.14 (1.05 to
Venous thromboembolism - broad	BNT162b2	829	122,953	569	499.3	1.24)
	SARS-CoV-2 PCR	298,45				7.61 (7.05 to
Venous thromboembolism - broad	positive test	3	40,439	664	87.3	8.21)

	Vaccinated with	1,945,				1.10 (1.01 to
Venous thromboembolism - narrow	ChAdOx1	919	123,883	508	463.2	•
	Vaccinated with	1,723,				1.09 (1.00 to
Venous thromboembolism - narrow	BNT162b2	490	123,001	526	482.9	1.19)
	SARS-CoV-2 PCR	298,52				7.76 (7.19 to
Venous thromboembolism - narrow	positive test	1	40,450	646	83.2	8.39)
Venous thromboembolism broad with thrombocytopenia 10 days	Vaccinated with	1,956,				1.66 (0.94 to
pre to 10 days post	ChAdOx1	082	124,564	12	7.2	2.92)
Venous thromboembolism broad with thrombocytopenia 10 days	Vaccinated with	1,731,				0.92 (0.44 to
pre to 10 days post	BNT162b2	858	123,609	7	7.6	1.93)
Venous thromboembolism broad with thrombocytopenia 42 days	Vaccinated with	1,956,				1.29 (0.80 to
pre to 14 days post	ChAdOx1	004	124,558	17	13.2	2.07)
Venous thromboembolism broad with thrombocytopenia 42 days	Vaccinated with	1,731,				0.79 (0.44 to
pre to 14 days post	BNT162b2	794	123,604	11	13.9	1.42)
Venous thromboembolism broad with thrombocytopenia 42 days	SARS-CoV-2 PCR	299,32				3.46 (1.55 to
pre to 14 days post	positive test	4	40,617	6	1.7	7.69)
Venous thromboembolism narrow with thrombocytopenia 10 days	Vaccinated with	1,956,				1.28 (0.67 to
pre to 10 days post	ChAdOx1	088	124,564	9	7	2.47)
Venous thromboembolism narrow with thrombocytopenia 10 days	Vaccinated with	1,731,				0.94 (0.45 to
pre to 10 days post	BNT162b2	863	123,610	7	7.4	1.98)
Venous thromboembolism narrow with thrombocytopenia 42 days	Vaccinated with	1,956,				1.09 (0.64 to
pre to 14 days post	ChAdOx1	011	124,559	14	12.9	1.83)
Venous thromboembolism narrow with thrombocytopenia 42 days	Vaccinated with	1,731,				0.81 (0.45 to
pre to 14 days post	BNT162b2	801	123,605	11	13.6	1.46)
Venous thromboembolism narrow with thrombocytopenia 42 days	SARS-CoV-2 PCR	299,32				3.59 (1.61 to
pre to 14 days post	positive test	4	40,617	6	1.7	8.00)

Results with general population identified as of 1st December 2017

For each event of interest the number of persons contributing to the analysis from the target population, their person-years contributed, and the number of events observed for them are given. Their expected events are estimated using indirect standardisation to the general population, with expected events giving the number of events we would have expected to have seen if their outcome experience was the same as that of the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with less than 5 occurrences have been omitted for privacy reasons. *Cerebral venous sinus thrombosis is reported without the requirement for a year of prior history as less than 5 events were seen when this restriction was imposed.

Event	Cohort	N	Person- vears	Observed events	Expected events	SIR (95% CI)
	Vaccinated with	1,956,	years	events	events	2.70 (1.13 to
Cerebral venous sinus thrombosis*	ChAdOx1	136	124,569	5	1.8	6.49)
	Vaccinated with	1,862,				1.15 (1.02 to
Deep vein thrombosis - broad	ChAdOx1	896	118,757	275	239.4	1.29)
	Vaccinated with	1,656,				1.19 (1.06 to
Deep vein thrombosis - broad	BNT162b2	235	118,297	296	249.7	1.33)
	SARS-CoV-2 PCR	298,70				3.05 (2.59 to
Deep vein thrombosis - broad	positive test	7	40,517	143	46.9	3.59)
	Vaccinated with	1,863,				1.01 (0.89 to
Deep vein thrombosis - narrow	ChAdOx1	668	118,809	226	223.2	1.15)
	Vaccinated with	1,656,				1.09 (0.96 to
Deep vein thrombosis - narrow	BNT162b2	875	118,344	254	234	1.23)
	SARS-CoV-2 PCR	298,77				2.90 (2.44 to
Deep vein thrombosis - narrow	positive test	6	40,528	125	43	3.46)
Deep vein thrombosis broad with thrombocytopenia 10 days pre to	Vaccinated with	1,868,				1.55 (0.70 to
10 days post	ChAdOx1	584	119,135	6	3.9	3.45)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to	Vaccinated with	1,868,				1.30 (0.68 to
14 days post	ChAdOx1	547	119,132	9	6.9	2.51)
Deep vein thrombosis narrow with thrombocytopenia 42 days pre	Vaccinated with	1,868,				1.07 (0.51 to
to 14 days post	ChAdOx1	554	119,133	7	6.5	2.25)
	Vaccinated with	1,867,				1.10 (0.82 to
Hemorrhagic stroke	ChAdOx1	822	119,084	45	40.9	1.47)


	Vaccinated with	1,660,				0.86 (0.62 to
Hemorrhagic stroke	BNT162b2	431	118,603	38	44.3	1.18)
	SARS-CoV-2 PCR	299,12				1.47 (0.82 to
Hemorrhagic stroke	positive test	7	40,584	11	7.5	2.66)
	Vaccinated with	1,868,				2.15 (1.35 to
Immune thrombocytopenia	ChAdOx1	376	119,120	18	8.4	3.41)
	Vaccinated with	1,660,				1.87 (1.13 to
Immune thrombocytopenia	BNT162b2	786	118,628	15	8	3.11)
	SARS-CoV-2 PCR	299,17				3.23 (1.35 to
Immune thrombocytopenia	positive test	5	40,593	5	1.5	7.77)
	Vaccinated with	1,868,				0.91 (0.53 to
Intestinal infarction	ChAdOx1	365	119,120	13	14.3	1.56)
	Vaccinated with	1,660,				1.16 (0.72 to
Intestinal infarction	BNT162b2	825	118,631	17	14.6	1.87)
	Vaccinated with	1,867,				0.79 (0.63 to
Ischemic stroke	ChAdOx1	000	119,025	72	91.2	0.99)
	Vaccinated with	1,659,				1.17 (0.98 to
Ischemic stroke	BNT162b2	635	118,542	120	102.6	1.40)
	SARS-CoV-2 PCR	299,10				1.14 (0.66 to
Ischemic stroke	positive test	0	40,582	13	11.4	1.96)
	Vaccinated with	1,861,				0.89 (0.80 to
Myocardial infarction	ChAdOx1	365	118,643	347	391.6	0.98)
	Vaccinated with	1,654,				0.87 (0.78 to
Myocardial infarction	BNT162b2	037	118,145	356	409.8	0.96)
	SARS-CoV-2 PCR	298,63				1.29 (1.04 to
Myocardial infarction	positive test	2	40,509	79	61.1	1.61)
	Vaccinated with	1,858,				0.85 (0.77 to
Myocardial infarction or ischemic stroke	ChAdOx1	974	118,481	406	479.5	0.93)
	Vaccinated with	1,651,				0.90 (0.82 to
Myocardial infarction or ischemic stroke	BNT162b2	903	117,990	458	508.9	0.99)
	SARS-CoV-2 PCR	298,46				1.22 (0.99 to
Myocardial infarction or ischemic stroke	positive test	4	40,485	88	72.1	1.50)

Myocardial infarction or ischemic stroke with thrombocytopenia 10	Vaccinated with	1,868,				1.66 (0.69 to
days pre to 10 days post	ChAdOx1	580	119,135	5	3	3.99)
Myocardial infarction or ischemic stroke with thrombocytopenia 42	Vaccinated with	1,868,				1.62 (0.87 to
days pre to 14 days post	ChAdOx1	524	119,131	10	6.2	3.02)
Myocardial infarction or ischemic stroke with thrombocytopenia 42	Vaccinated with	1,660,				0.77 (0.35 to
days pre to 14 days post	BNT162b2	931	118,639	6	7.8	1.71)
	Vaccinated with	1,865,				2.44 (2.12 to
Platelet disorder	ChAdOx1	323	118,905	198	81.2	2.80)
	Vaccinated with	1,657,				2.12 (1.83 to
Platelet disorder	BNT162b2	943	118,416	174	82	2.46)
	SARS-CoV-2 PCR	298,92				4.08 (3.14 to
Platelet disorder	positive test	2	40,552	57	14	5.28)
	Vaccinated with	1,868,				1.55 (0.77 to
Portal vein thrombosis	ChAdOx1	539	119,133	8	5.2	3.09)
	Vaccinated with	1,863,				1.30 (1.15 to
Pulmonary embolism	ChAdOx1	403	118,787	259	198.7	1.47)
	Vaccinated with	1,656,				1.29 (1.14 to
Pulmonary embolism	BNT162b2	755	118,336	261	202.8	1.45)
	SARS-CoV-2 PCR	298,78				17.09 (15.72 to
Pulmonary embolism	positive test	6	40,491	547	32	18.58)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	Vaccinated with	1,868,				1.16 (0.52 to
days post	ChAdOx1	576	119,134	6	5.2	2.58)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	Vaccinated with	1,660,				1.27 (0.60 to
days post	BNT162b2	999	118,644	7	5.5	2.65)
Pulmonary embolism with thrombocytopenia 42 days pre to 14	SARS-CoV-2 PCR	299,20				9.05 (4.07 to
days post	positive test	8	40,596	6	0.7	20.14)
	Vaccinated with	1,868,				1.46 (0.76 to
Splanchnic Vein Thrombosis	ChAdOx1	536	119,132	9	6.2	2.80)
	Vaccinated with	1,861,				1.07 (0.97 to
Stroke	ChAdOx1	358	118,629	413	385.8	,
	Vaccinated with	1,654,				1.06 (0.97 to
Stroke	BNT162b2	569	118,167	457	429.2	1.17)

	SARS-CoV-2 PCR	298,70				1.29 (1.01 to
Stroke	positive test	9	40,525	65	50.4	1.64)
	Vaccinated with	1,868,				2.32 (1.04 to
Stroke with thrombocytopenia 10 days pre to 10 days post	ChAdOx1	605	119,136	6	2.6	5.16)
	Vaccinated with	1,868,				1.09 (0.49 to
Stroke with thrombocytopenia 42 days pre to 14 days post	ChAdOx1	573	119,134	6	5.5	2.43)
	Vaccinated with	1,660,				1.24 (0.62 to
Stroke with thrombocytopenia 42 days pre to 14 days post	BNT162b2	982	118,643	8	6.5	2.47)
	Vaccinated with	1,840,				1.33 (1.27 to
Thrombocytopenia	ChAdOx1	495	117,121	1,707	1,281.00	1.40)
	Vaccinated with	1,632,				1.07 (1.01 to
Thrombocytopenia	BNT162b2	328	116,491	1,462	1,372.60	1.12)
	SARS-CoV-2 PCR	296,99				1.16 (1.03 to
Thrombocytopenia	positive test	9	40,289	254	218.9	1.31)
	Vaccinated with	1,868,				1.59 (0.90 to
Thrombocytopenic purpura	ChAdOx1	562	119,134	12	7.5	2.80)
	Vaccinated with	1,660,				0.68 (0.28 to
Thrombocytopenic purpura	BNT162b2	955	118,641	5	7.3	1.64)
	Vaccinated with	1,858,				1.21 (1.11 to
Venous thromboembolism - broad	ChAdOx1	064	118,431	508	419.1	1.32)
	Vaccinated with	1,652,				1.23 (1.13 to
Venous thromboembolism - broad	BNT162b2	244	118,007	532	433.9	1.33)
	SARS-CoV-2 PCR	298,32				8.88 (8.23 to
Venous thromboembolism - broad	positive test	9	40,418	664	74.8	9.58)
	Vaccinated with	1,858,				1.14 (1.04 to
Venous thromboembolism - narrow	ChAdOx1	837	118,483	461	403.9	'
	Vaccinated with	1,652,				1.17 (1.07 to
Venous thromboembolism - narrow	BNT162b2	892	118,054	491	419	1.28)
	SARS-CoV-2 PCR	298,39				9.09 (8.42 to
Venous thromboembolism - narrow	positive test	7	40,429	646	71.1	9.82)
Venous thromboembolism broad with thrombocytopenia 10 days	Vaccinated with	1,868,				1.44 (0.75 to
pre to 10 days post	ChAdOx1	543	119,132	9	6.2	2.77)

Venous thromboembolism broad with thrombocytopenia 10 days	Vaccinated with	1,660,				0.90 (0.41 to
pre to 10 days post	BNT162b2	959	118,641	6	6.7	2.01)
Venous thromboembolism broad with thrombocytopenia 42 days	Vaccinated with	1,868,				1.21 (0.72 to
pre to 14 days post	ChAdOx1	467	119,126	14	11.6	2.04)
Venous thromboembolism broad with thrombocytopenia 42 days	Vaccinated with	1,660,				0.81 (0.43 to
pre to 14 days post	BNT162b2	896	118,636	10	12.4	1.50)
Venous thromboembolism broad with thrombocytopenia 42 days	SARS-CoV-2 PCR	299,19				3.93 (1.77 to
pre to 14 days post	positive test	9	40,595	6	1.5	8.76)
Venous thromboembolism narrow with thrombocytopenia 10 days	Vaccinated with	1,868,				1.16 (0.56 to
pre to 10 days post	ChAdOx1	547	119,132	7	6	2.44)
Venous thromboembolism narrow with thrombocytopenia 10 days	Vaccinated with	1,660,				0.93 (0.42 to
pre to 10 days post	BNT162b2	964	118,641	6	6.5	2.06)
Venous thromboembolism narrow with thrombocytopenia 42 days	Vaccinated with	1,868,				1.07 (0.61 to
pre to 14 days post	ChAdOx1	472	119,127	12	11.3	1.88)
Venous thromboembolism narrow with thrombocytopenia 42 days	Vaccinated with	1,660,				0.83 (0.44 to
pre to 14 days post	BNT162b2	903	118,637	10	12.1	1.54)
Venous thromboembolism narrow with thrombocytopenia 42 days	SARS-CoV-2 PCR	299,19				4.11 (1.85 to
pre to 14 days post	positive test	9	40,595	6	1.5	9.14)

Incidence rate ratios (IRRs) and 95% confidence intervals for pulmonary embolism stratified by age, sex, and calendar month



◆ Vaccinated with BNT162b2 ◆ Vaccinated with ChAdOx1 ◆ All ◆ December ● January + February


Patient profiles: pulmonary embolism

The characteristics of persons with pulmonary embolism used for the primary analyses. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. [†]Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

<u> </u>	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2
N	7,414	281	282
Age	68 [56 to 77]	74 [67 to 79]	75 [66 to 82]
Age: 30 to 39	474 (6.4%)	<5	6 (2.1%)
Age: 40 to 49	735 (9.9%)	12 (4.3%)	14 (5.0%)
Age: 50 to 59	1,164 (15.7%)	30 (10.7%)	23 (8.2%)
Age: 60 to 69	1,666 (22.5%)	49 (17.4%)	51 (18.1%)
Age: 70 to 79	1,918 (25.9%)	119 (42.3%)	89 (31.6%)
Age: 80 or older	1,457 (19.7%)	69 (24.6%)	99 (35.1%)
Sex: Male	3,543 (47.8%)	138 (49.1%)	135 (47.9%)
Years of prior observation time	14.9 [7.9 to 17.6]	17.8 [6.0 to 32.5]	21.5 [8.7 to 34.9]
Comorbidities			
Autoimmune disease	325 (4.4%)	13 (4.6%)	18 (6.4%)
Antiphospholipid syndrome	14 (0.2%)	0 (0.0%)	0 (0.0%)
Thrombophilia	36 (0.5%)	0 (0.0%)	0 (0.0%)
Asthma	1,137 (15.3%)	43 (15.3%)	39 (13.8%)
Atrial fibrillation	302 (4.1%)	19 (6.8%)	14 (5.0%)
Malignant neoplastic disease	1,533 (20.7%)	91 (32.4%)	94 (33.3%)
Diabetes mellitus	974 (13.1%)	51 (18.1%)	46 (16.3%)
Obesity	556 (7.5%)	23 (8.2%)	21 (7.4%)
Heart disease	1,382 (18.6%)	73 (26.0%)	64 (22.7%)
Hypertensive disorder	2,832 (38.2%)	120 (42.7%)	129 (45.7%)
Renal impairment	1,131 (15.3%)	63 (22.4%)	71 (25.2%)

COPD	674 (9.1%)	31 (11.0%)	33 (11.7%)
Dementia	176 (2.4%)	23 (8.2%)	11 (3.9%)
Medication use (183 days prior to four days prior)			
Non-steroidal anti-inflammatory drugs	4,302 (58.0%)	87 (31.0%)	77 (27.3%)
Cox2 inhibitors	42 (0.6%)	0 (0.0%)	<5
Systemic corticosteroids	2,001 (27.0%)	43 (15.3%)	34 (12.1%)
Antithrombotic and anticoagulant therapies	1,555 (21.0%)	35 (12.5%)	32 (11.3%)
Lipid modifying agents	890 (12.0%)	29 (10.3%)	23 (8.2%)
Antineoplastic and immunomodulating agents	387 (5.2%)	11 (3.9%)	12 (4.3%)
Hormonal contraceptives for systemic use	158 (2.1%)	<5	6 (2.1%)
Tamoxifen	39 (0.5%)	<5	<5
Sex hormones and modulators of the genital system	295 (4.0%)	9 (3.2%)	9 (3.2%)
One or more condition of interest*	3,388 (45.7%)	165 (58.7%)	176 (62.4%)
One or more medication of interest [†]	4,746 (64.0%)	108 (38.4%)	100 (35.5%)
One or more condition/ medication of interest* [†]	5,745 (77.5%)	199 (70.8%)	207 (73.4%)

Incidence rate ratios (IRRs) and 95% confidence intervals for thrombocytopenia stratified by age, sex, and calendar month



Patient profiles: thrombocytopenia

The characteristics of persons with thrombocytopenia used for the primary analyses. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. [†]Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2
Ν	50,690	1,865	1,548
Age	67 [53 to 78]	73 [64 to 79]	78 [68 to 85]
Age: 30 to 39	4,604 (9.1%)	54 (2.9%)	31 (2.0%)
Age: 40 to 49	5,289 (10.4%)	101 (5.4%)	68 (4.4%)
Age: 50 to 59	7,994 (15.8%)	176 (9.4%)	129 (8.3%)
Age: 60 to 69	10,130 (20.0%)	379 (20.3%)	199 (12.9%)
Age: 70 to 79	11,963 (23.6%)	728 (39.0%)	431 (27.8%)
Age: 80 or older	10,710 (21.1%)	427 (22.9%)	690 (44.6%)
Sex: Male	31,064 (61.3%)	1,181 (63.3%)	1,022 (66.0%)
Years of prior observation time	14.4 [5.9 to 17.2]	16.9 [5.5 to 31.3]	22.1 [7.3 to 33.6]
Comorbidities			
Autoimmune disease	2,551 (5.0%)	134 (7.2%)	128 (8.3%)
Antiphospholipid syndrome	40 (0.1%)	5 (0.3%)	<5
Thrombophilia	73 (0.1%)	8 (0.4%)	6 (0.4%)
Asthma	5,755 (11.4%)	223 (12.0%)	170 (11.0%)
Atrial fibrillation	6,002 (11.8%)	341 (18.3%)	408 (26.4%)
Malignant neoplastic disease	8,691 (17.1%)	451 (24.2%)	441 (28.5%)
Diabetes mellitus	9,211 (18.2%)	542 (29.1%)	431 (27.8%)
Obesity	2,819 (5.6%)	169 (9.1%)	90 (5.8%)
Heart disease	14,636 (28.9%)	764 (41.0%)	765 (49.4%)
Hypertensive disorder	20,144 (39.7%)	990 (53.1%)	900 (58.1%)
Renal impairment	8,695 (17.2%)	457 (24.5%)	491 (31.7%)

COPD	3,023 (6.0%)	166 (8.9%)	139 (9.0%)
Dementia	1,421 (2.8%)	109 (5.8%)	58 (3.7%)
Medication use (183 days prior to four days prior)			
Non-steroidal anti-inflammatory drugs	27,424 (54.1%)	587 (31.5%)	543 (35.1%)
Cox2 inhibitors	293 (0.6%)	7 (0.4%)	6 (0.4%)
Systemic corticosteroids	13,729 (27.1%)	301 (16.1%)	266 (17.2%)
Antithrombotic and anticoagulant therapies	9,624 (19.0%)	226 (12.1%)	254 (16.4%)
Lipid modifying agents	8,093 (16.0%)	249 (13.4%)	248 (16.0%)
Antineoplastic and immunomodulating agents	2,793 (5.5%)	48 (2.6%)	47 (3.0%)
Hormonal contraceptives for systemic use	976 (1.9%)	12 (0.6%)	12 (0.8%)
Tamoxifen	137 (0.3%)	0 (0.0%)	<5
Sex hormones and modulators of the genital system	1,878 (3.7%)	36 (1.9%)	27 (1.7%)
One or more condition of interest*	25,148 (49.6%)	1,271 (68.2%)	1,160 (74.9%)
One or more medication of interest [†]	30,447 (60.1%)	670 (35.9%)	625 (40.4%)
One or more condition/ medication of interest* [†]	38,782 (76.5%)	1,448 (77.6%)	1,298 (83.9%)